NEXGEL (NXGL) 10-K 27 Mar 23 2022 FY Annual report Financial data

Cover

Cover - USD ($)	12 Months Ended
	Dec. 31, 2022	Mar. 27, 2023	Jun. 30, 2022
Document Type	10-K
Amendment Flag	false
Document Annual Report	true
Document Transition Report	false
Document Period End Date	Dec. 31, 2022
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2022
Current Fiscal Year End Date	--12-31
Entity File Number	001-41173
Entity Registrant Name	NexGel, Inc.
Entity Central Index Key	0001468929
Entity Tax Identification Number	26-4042544
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	2150 Cabot Blvd West
Entity Address, Address Line Two	Suite B
Entity Address, City or Town	Langhorne
Entity Address, State or Province	PA
Entity Address, Postal Zip Code	19047
City Area Code	(215)
Local Phone Number	702-8550
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	No
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false
Entity Shell Company	false
Entity Public Float			$ 7,524,481
Entity Common Stock, Shares Outstanding		5,611,282
Documents Incorporated by Reference	Portions of the registrant’s definitive proxy statement relating to its 2023 annual meeting of stockholders (the “2023 Proxy Statement”) are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated. The 2023 Proxy Statement will be filed with the U.S. Securities and Exchange Commission within 120 days after the end of the year to which this report relates.
Auditor Firm ID	76
Auditor Name	Turner, Stone & Company, L.L.P
Auditor Location	Dallas, Texas
Common Stock Par Value 0.001 [Member]
Title of 12(b) Security	Common Stock, par value $0.001
Trading Symbol	NXGL
Security Exchange Name	NASDAQ
Warrants To Purchase Common Stock [Member]
Title of 12(b) Security	Warrants to Purchase Common Stock
Trading Symbol	NXGLW
Security Exchange Name	NASDAQ

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Current Assets:
Cash	$ 1,101	$ 13,350
Marketable securities	5,508
Accounts receivable, net	222	209
Inventory	502	291
Prepaid expenses and other current assets	172	77
Total current assets	7,505	13,927
Goodwill	311	311
Intangibles, net	20	33
Property and equipment, net	721	723
Operating lease - right of use asset	1,737	1,926
Other assets	63	63
Total assets	10,357	16,983
Current Liabilities:
Accounts payable	265	254
Accrued expenses and other current liabilities	130	62
Convertible notes payable, net of deferred financing costs		2,037
Notes payable, current portion	15	10
Warrant liability	242	318
Operating lease liability, current portion	207	207
Total current liabilities	859	2,888
Operating lease liability, net of current portion	1,593	1,744
Notes payable, net of current portion	268	266
Total liabilities	2,720	4,898
Commitments and Contingencies (Note 15)
Preferred stock, par value $0.001 per share, 5,000,000 shares authorized, no shares issued and outstanding
Common stock, par value $0.001 per share, 25,000,000 shares authorized; 5,577,916 and 5,572,234 shares issued and outstanding as of both December 31, 2022 and 2021	6	6
Additional paid-in capital	19,189	18,891
Accumulated deficit	(11,558)	(6,812)
Total stockholders’ equity	7,637	12,085
Total liabilities and stockholders’ equity	$ 10,357	$ 16,983

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	25,000,000	25,000,000
Common stock, shares issued	5,577,916	5,572,234
Common stock, shares outstanding	5,577,916	5,572,234

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Income Statement [Abstract]
Revenues, net	$ 2,048	$ 1,551
Cost of revenues	1,792	1,543
Gross profit	256	8
Operating expenses
Research and development	367	31
Selling, general and administrative	3,237	2,547
Total operating expenses	3,604	2,578
Loss from operations	(3,348)	(2,570)
Other income (expense)
Change in fair value of warrant liability and warrant modification expense	76	8
Forgiveness of debt		275
Debt financing costs		(68)
Unrealized gain on investments in marketable securities	9
Loss on debt extinguishment	(150)	(25)
Interest expense	(1,336)	(1,930)
Other income	3
Total other income (expense)	(1,398)	(1,740)
Net loss	$ (4,746)	$ (4,310)
Net loss per common share – basic and diluted	$ (0.85)	$ (1.45)
Weighted average shares used in computing net loss per common share – basic and diluted	5,574,818	2,979,962

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Dec. 31, 2020	$ 3	$ 2,570	$ (2,502)	$ 71
Beginning balance, shares at Dec. 31, 2020	2,838,047
Issuance of common stock, net of issuance costs	$ 3	13,468		13,471
Issuances of common stock, net of issuance costs, shares	2,686,800
Restricted stock vesting		61		61
Restricted stock vesting, shares	39,524
Beneficial conversion and warrant features of convertible debt		2,587		2,587
Exercise of stock options
Exercise of stock options, shares	7,183
Stock-based compensation		223		223
Derivative liability - COVA		(18)		(18)
Share adjustment for stock split rounding
Share adjustment for stock split rounding, shares	680
Net loss			(4,310)	(4,310)
Ending balance, value at Dec. 31, 2021	$ 6	18,891	(6,812)	12,085
Ending balance, shares at Dec. 31, 2021	5,572,234
Restricted stock vesting		67		$ 67
Restricted stock vesting, shares	5,682			90,432
Stock-based compensation		231		$ 231
Net loss			(4,746)	(4,746)
Ending balance, value at Dec. 31, 2022	$ 6	$ 19,189	$ (11,558)	$ 7,637
Ending balance, shares at Dec. 31, 2022	5,577,916

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Operating Activities
Net loss	$ (4,746)	$ (4,310)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	112	113
Share-based compensation	298	285
Gain on investment in marketable securities	(9)
Changes in fair value of warrant liability	(133)	(8)
Warrant modification expense	57	52
Forgiveness of debt		(275)
Amortization of right of use asset	189	25
Loss of extinguishment of debt	150	25
Amortization of deferred financing costs	1,324	1,933
Changes in operating assets and liabilities:
Accounts receivable, net	(13)	(137)
Inventory	(211)	(58)
Prepaid expenses and other current assets	(95)	63
Accounts payable	11	(405)
Accrued expenses and other current liabilities	74	(18)
Deferred revenue		(38)
Net Cash Used in Operating Activities	(2,992)	(2,753)
Investing Activities
Purchases of equipment	(96)	(269)
Proceeds from sales of marketable securities	1,500
Investments in or Purchases of marketable securities	(6,999)
Net Cash Used in Investing Activities	(5,595)	(269)
Financing Activities
Principal payments on operating lease liability	(151)
Issuance of common stock, net of issuance costs		13,471
Proceeds from notes payable		15
Proceeds from convertible notes		2,957
Payment of financing costs		(115)
Principal payments of notes payable		(15)
Principal payments on convertible notes	(3,511)	(100)
Proceeds from notes payable (PPP)		127
Net Cash Used in Financing Activities	(3,662)	16,340
Net Increase (Decrease) in Cash	(12,249)	13,318
Cash  – Beginning of year	13,350	32
Cash – End of year	1,101	13,350
Supplemental Non-cash Investing and Financing Activities
Fair value of beneficial conversion and warrant features of convertible notes payable		2,587
Original issue discounts recognized on convertible notes payable		653
Warrants issued for debt and equity financing costs		203
Operating lease, ROU assets and liabilities		$ 2,050

Description of Business, Stock

Description of Business, Stock Split and Basis of Presentation	12 Months Ended
	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business, Stock Split and Basis of Presentation	1. Description of Business, Stock Split and Basis of Presentation NexGel, Inc. (“NexGel” or the “Company”) manufactures high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery and cosmetics. The Company specializes in custom gels by capitalizing on proprietary manufacturing technologies. NexGel has historically served as a contract manufacturer, supplying our gels to third parties who incorporate them into their own products, and has recently began producing the Company’s own consumer products using our gels focused on proprietary branded products and white label opportunities. Both the Company’s gels and consumer products are manufactured using proprietary and non-proprietary mixing, coating and cross-linking technologies. Together, these technologies enable NexGel to produce gels that can satisfy rigid tolerance specifications with respect to a wide range of physical characteristics (e.g., thickness, water content, adherence, absorption, moisture vapor transmission rate (a measure of the passage of water vapor through a substance) and release rate) while maintaining product integrity. Additionally, the Company has the manufacturing capability to offer broad choices in the selection of liners onto which the gels are coated. Consequently, NexGel and our customers are able to determine tolerances in moisture vapor transmission rate and active ingredient release rates while personalizing color and texture. NexGel was previously known as AquaMed Technologies, Inc. (“AquaMed”) before changing its name to NexGel, Inc. on November 14, 2019. The accompanying consolidated financial statements include the accounts of the Company and its consolidated wholly-owned subsidiary, NexGelRx, Inc. Stock Split On November 29, 2021, the Company effected a 1-for-35 reverse stock split 0.001 Basis of Presentation The consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) and are presented in US dollars.

Going Concern

Going Concern	12 Months Ended
	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern	2. Going Concern As of December 31, 2022, the Company had a cash balance of $ 1.1 5.5 4.7 3.0 6.6 On December 27, 2021, the Company sold an aggregate of 2,585,000 5.50 5.50 14.2 Management is exploring new product channel sales in adjacent industries, such as cosmetics, athletic products, and proprietary medical devices. The Company has increased focus on sales and developing a sales pipeline for potential customers. This customer base expansion will enable us to provide financial stability for the foreseeable future, expand our current processes, and position us for long-term shareholder value creation. We have sufficient capital to maintain as a going concern due to the capital raise that occurred on December 27, 2021. We intend to maintain and attempt to grow our existing contract manufacturing business. We also plan to continue building and developing our catalog of consumer products for sale to branding partners and to use our in-house capabilities to create and test market additional branded products. These products will be target marketed and sold online through social media, television and online marketplaces. Furthermore, the Company plans to develop its own proprietary medical devices and explore drug delivery programs for its technology. Additionally, the Company continues to evaluate strategic initiatives (e.g., acquisitions) and additional capital raises through debt or equity may be necessary to achieve these objectives. We expect to continue incurring losses for the near-term future. Our ability to continue to operate as a going concern in the long-term is dependent upon our ability to manage and grow our current products and to ultimately achieve profitable operations. Management may consider various options to raise capital to fund potential acquisitions through equity or debt offerings. There can be no assurances, however, that management will be able to obtain sufficient additional funds, if needed, or that such funds, if available, will be obtained on terms satisfactory to us. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded assets and liabilities that might be necessary should we be unable to continue as a going concern. Additionally, it is reasonably possible that estimates made in the consolidated financial statements have been, or will be, materially and adversely impacted in the near term as a result of these conditions, including the recoverability of long-lived assets.

Significant Accounting Policies

Significant Accounting Policies and Estimates	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Significant Accounting Policies and Estimates	3. Significant Accounting Policies and Estimates Use of Estimates The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. These estimates and assumptions include allowances for doubtful accounts, inventory reserves, deferred taxes, share-based compensation and related valuation allowances and fair value of long-lived assets. Actual results could differ from the estimates. Reclassifications We have reclassified, combined or separately disclosed certain amounts in the prior years’ consolidated financial statements and accompanying footnotes to conform with the current year’s presentation. Cash Cash is comprised of cash in banks and highly liquid investments, including U.S. treasury bills purchased with an original maturity of three months or less as well as investments in money market funds for which the carrying amount approximates fair value, due to the short maturities of these investments. Marketable Securities The Company classifies its marketable securities as held-to-maturity, which include U.S. treasury bills with original maturities of greater than three months. These securities are carried at fair value with any change in fair value recorded as an unrealized gain (loss) in the statement of operations of the year in which such change occurs. The total unrealized gain related to the marketable securities was inconsequential during the year ended December 31, 2022. The Company had no marketable securities as of December 31, 2021. Schedule of Marketable Securities December 31, 2022 Marketable Securities United States treasury bills (due February 23, 2023) $ 492 United States treasury bills (due April 27, 2023) 20 United States treasury bills (due June 15, 2023) 4,384 United States treasury bills (due July 13, 2023) 127 United States treasury bills (due August 10, 2023) 485 Total $ 5,508 Accounts Receivable, net Trade accounts receivable are stated at the amount the Company expects to collect and do not bear interest. The Company evaluates the collectability of accounts receivable and records a provision to the allowance for doubtful accounts based on factors including the length of time the receivables are past due, the current business environment and the Company’s historical experience. Provisions to the allowances for doubtful accounts are recorded in selling, general and administrative expenses. Account balances are charged off against the allowance when it is probable that the receivable will not be recovered. The allowance for doubtful accounts was $ 9 4 Inventory and Cost of Revenues Inventory is stated at the lower of cost, the value determined by the first-in, first-out method, or net realizable value. The Company evaluates inventories for excess quantities, obsolescence, and shelf-life expiration. This evaluation includes an analysis of historical sales levels by product, projections of future demand, the risk of technological or competitive obsolescence for products, general market conditions, and a review of the shelf-life expiration dates for products. These factors determine when, and if, the Company adjusts the carrying value of inventory to estimated net realizable value. The Company produces proprietary branded products and white label opportunities in our manufacturing of consumer products. In our contract manufacturing, the Company builds its products based on customer orders and immediately ships the products upon completion of the production process. The balance is made up of raw materials, work-in-progress, and finished goods of $ 295 51 156 178 88 25 The “Cost of revenues” line item in the consolidated statements of operations is comprised of the book value of inventory sold to customers during the reporting period. When circumstances dictate that we use net realizable value as the basis for recording inventory, we base our estimates on expected future selling prices less expected disposal costs. Research and Development Our research and development activities focus on new and innovative products designed to support revenue growth. Research and development expenses consist primarily of contracted development and testing efforts associated with development of products. Shipping and Handling Revenue and Expense Shipping and handling revenue and expense are included in our consolidated statements of operations in revenues and cost of revenues, respectively. This is primarily through shipping fees incurred in the Amazon marketplace. Property and Equipment, net Property and equipment is recorded at historical cost, net of accumulated depreciation and amortization. Depreciation is provided over the assets’ useful lives on a straight-line basis. Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or lease terms. Repairs and maintenance costs are expensed as incurred. Management periodically assesses the estimated useful life over which assets are depreciated or amortized. If the analysis warrants a change in the estimated useful life of property and equipment, management will reduce the estimated useful life and depreciate or amortize the carrying value prospectively over the shorter remaining useful life. The carrying amounts of assets sold or retired and the related accumulated depreciation are eliminated in the year of disposal and any resulting gains and losses are included in the results of operations during the same year. Impairment of Long-Lived Assets The Company reviews its property and equipment and any identifiable intangibles for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted operating cash flow expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value of the asset. Long-lived assets to be disposed of are reported at the lower of carrying amount or fair value less costs to sell. Goodwill and Intangible Assets In applying the acquisition method of accounting, amounts assigned to identifiable assets and liabilities acquired were based on estimated fair values as of the date of acquisition, with the remainder recorded as goodwill. Identifiable intangible assets are initially recorded at fair value using generally accepted valuation methods appropriate for the type of intangible asset. Identifiable intangible assets with definite lives are amortized over their estimated useful lives and are reviewed for impairment if indicators of impairment arise. Intangible assets with indefinite lives are tested for impairment within one year of acquisitions or annually as of December 31, and whenever indicators of impairment exist. The fair value of intangible assets is compared with their carrying values, and an impairment loss would be recognized for the amount by which a carrying amount exceeds its fair value. The Company performed the annual assessment and concluded it is more likely than not that the fair value exceeds the carrying value and no Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets are recorded at historical cost and is primarily made up of $ 63 23 109 54 Other Assets Other Assets is recorded at historical costs, and as of December 31, 2022 and 2021, the balance is primarily comprised of spare parts for manufacturing equipment. Other assets are stated at cost and are not subject to depreciation, until such time that they are placed into service and the part that is being replaced is disposed. Fair Value Measurements The Company utilizes the fair value hierarchy to apply fair value measurements. The fair value hierarchy is based on inputs to valuation techniques that are used to measure fair values that are either observable or unobservable. Observable inputs reflect assumptions market participants would use in pricing an asset or liability based on market data obtained from independent sources, while unobservable inputs reflect a reporting entity’s pricing based upon its own market assumptions. The basis for fair value measurements for each level within the hierarchy is described below: Level 1 Level 2 Level 3 The Company considers the carrying amounts of its financial instruments (cash, accounts receivable and accounts payable) in the balance sheet to approximate fair value because of the short-term or highly liquid nature of these financial instruments. The following table sets forth the fair value of the Company’s financial assets within the fair value hierarchy: Schedule of Fair Value of Financial Assets Level 1 Level 2 Level 3 Fair Value December 31, 2022 Level 1 Level 2 Level 3 Fair Value Assets Marketable securities: United States treasury bills $ 5,508 $ - $ - $ 5,508 Total $ 5,508 $ - $ - $ 5,508 Warrant Liability Warrants to purchase common stock were issued in connection with equity financing raises, which occurred during 2019 through 2021. The fair values of the warrants are estimated as of the date of issuance and again at each year end using a Black-Scholes option valuation model. At issuance, the fair values of the warrant are recognized as an equity issuance cost within additional paid-in-capital. Fair value adjustments to the warrant liability are recognized in other income (expense) in the statements of operations. Revenue Recognition On January 1, 2018, the Company adopted Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers The Company currently recognizes revenue predominately from three types of revenue, contract manufacturing, custom and white label finished goods manufacturing and our branded products. Revenues from manufactured products are recognized at the point where the customer obtains control of the goods and the Company satisfies its performance obligation, which generally is at the time the customer receives the product. The Company’s customers consist of other life sciences companies and Amazon retail customers. Revenues are entirely concentrated in the United States. Payment terms vary by the type and location of customer and may differ by jurisdiction and customer but payment is generally required in a term ranging from 30 to 60 days from date of shipment. Estimates for product returns, allowances and discounts are recorded as a reduction of revenue and are established at the time of sale. Returns are estimated through a comparison of historical return data and are determined for each product and adjusted for known or expected changes in the marketplace specific to each product, when appropriate. Historically, sales return provisions have not been material. Amounts accrued for sales allowances and discounts are based on estimates of amounts that are expected to be claimed on the related sales and are based on historical data. Payments for allowances and discounts have historically been immaterial. Disaggregated revenue by sales type: Schedule of Disaggregated Revenue by Sales Type 2022 2021 Year Ended December 31, 2022 2021 Contract manufacturing $ 1,033 $ 767 Custom and white label finished goods manufacturing 34 194 NexGel branded consumer products 815 488 Other 166 102 Total $ 2,048 $ 1,551 As of December 31, 2022 and 2021, the Company did not have any contract assets or contract liabilities from contracts with customers and there were no The Company has four distinct lines of business; Contract Manufacturing, Custom & White Label, Consumer Branded Products, and Medical Devices. Contract Manufacturing Customers order rolls of gel (“rollstock”). The rollstock is shipped to our customers, which they package into finished goods. Historically, this has been the Company’s primary source of revenue. Custom & White Label These products often infuse various ingredients into our base gel to develop unique product offerings to satisfy market demand (e.g. aloe infused into the gel for a beauty mask). The rollstock is converted and packaged into salable units. The finished goods are shipped to the customer, who is ultimately responsible for product distribution. Frequently these products started as development deals, in which the customer paid the Company a small fee to develop a specific product. Once completed, the customer places a large order for newly developed product. Consumer Branded Products These products are finished goods marketed and sold directly to the customer by the Company through online and retail channels. The Company is responsible for sales, marketing, and distribution. These products carry the Company’s brand names. Medical Devices Medical Devices are a hybrid business, combining elements of Custom & White Label and Consumer Branded Products. Medical Devices, which are not yet marketed, are expected to be distributed through strategic partnerships. The Company will manufacture and possibly convert/package the device while the strategic partner brings the product to market. Small market Medical Devices could be launched by the Company, but also be offered to a distributor to reach the full scale of the market. Share-based Compensation On August 28, 2019, the Company adopted the 2019 Long-Term Incentive Plan, as amended (the “2019 Plan”). See Note 10 and note 18 below for further details regarding the 2019 Plan. The 2019 Plan provides certain employees, contractors, and outside directors with share-based compensation in the form of incentive stock options, nonqualified stock options, stock appreciation rights, restricted stock, restricted stock units, performance awards, dividend equivalent rights and other awards. The fair values of incentive stock option award grants are estimated as of the date of grant using a Black-Scholes option valuation model. Compensation expense is recognized in the statements of operations on a straight-line basis over the requisite service period, which is generally the vesting period required to obtain full vesting. Forfeitures are accounted for when they occur. In June 2018, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2018-07, Compensation - Stock Compensation (Topic 718) - Improvements to Nonemployee Share-Based Payment Accounting Compensation - Stock Compensation Income Taxes Income taxes are accounted for using an asset and liability approach that requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the financial statement and tax bases of assets and liabilities at the applicable tax rates. Deferred tax assets are reduced by a valuation allowance when it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates. Tax benefits are recognized from an uncertain tax position only if it is more likely than not that the tax position will be sustained upon examination by a tax authority and based upon the technical merits of the tax position. The tax benefit recognized in the consolidated financial statements for a particular tax position is based on the largest benefit that is more likely than not to be realized upon settlement. An unrecognized tax benefit, or a portion thereof, is presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward if such settlement is required or expected in the event the uncertain tax position is disallowed. Leases ASC 842 requires recognition of leases on the consolidated balance sheets as right-of-use (“ROU”) assets and lease liabilities. ROU assets represent the Company’s right to use underlying assets for the lease terms and lease liabilities represent the Company’s obligation to make lease payments arising from the leases. Operating lease ROU assets and operating lease liabilities are recognized based on the present value and future minimum lease payments over the lease term at commencement date. As the Company’s leases do not provide an implicit rate, the Company used its estimated incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. A number of the lease agreements contain options to renew and options to terminate the leases early. The lease term used to calculate ROU assets and lease liabilities only includes renewal and termination options that are deemed reasonably certain to be exercised. The Company recognized lease liabilities, with corresponding ROU assets, based on the present value of unpaid lease payments for existing operating leases longer than twelve months. The ROU assets were adjusted per ASC 842 transition guidance for existing lease-related balances of accrued and prepaid rent, and unamortized lease incentives provided by lessors. Operating lease cost is recognized as a single lease cost on a straight-line basis over the lease term and is recorded in selling, general and administrative expenses. Variable lease payments for common area maintenance, property taxes and other operating expenses are recognized as expense in the year when the changes in facts and circumstances on which the variable lease payments are based occur. The Company has elected not to separate lease and non-lease components for all property leases for the purposes of calculating ROU assets and lease liabilities. Segment reporting The Company operates in one Comprehensive loss Comprehensive loss consists of net loss and changes in equity during a year from transactions and other equity and circumstances generated from non-owner sources. The Company’s net loss equals comprehensive loss for all years presented, Recently Issued Accounting Standards From time to time, new accounting pronouncements are issued by the FASB, or other standard setting bodies and adopted by us as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on our consolidated financial position or results of operations upon adoption. In June 2016, FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments In January 2017, the FASB issued ASU 2017-04, Intangibles—Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes

Leases

Leases	12 Months Ended
	Dec. 31, 2022
Leases
Leases	4. Leases The Company has one operating lease for a commercial manufacturing facility and administrative offices located in Langhorne, Pennsylvania that runs through January 2031. There are two options that can extend the lease term for five years each. The exercise of the lease options to renew is solely at the Company’s discretion. The following table presents information about the amount and timing of the liability arising from the Company’s operating lease as of December 31, 2022 ($ in thousands): Schedule of Future Minimum Lease Payments Maturity of Lease Liability Operating 2023 $ 207 2024 207 2025 207 2026 263 2027 274 Thereafter 890 Total undiscounted operating lease payments $ 2,048 Less: Imputed interest (248 ) Present value of operating lease liability $ 1,800 Weighted average remaining lease term 8.1 Weighted average discount rate 3.0 % Total operating lease expense for the year ended December 31, 2022 and 2021 was $ 246 233 Supplemental cash flows information related to leases was as follows ($ in thousands): Schedule of Supplemental Cash Flows Information Related to Leases December 31, 2022 Cash paid for amounts included in the measurement of lease liability: Operating cash flows from operating lease $ 207

Inventory

Inventory	12 Months Ended
	Dec. 31, 2022
Inventory Disclosure [Abstract]
Inventory	5. Inventory Inventory consists of the following ($ in thousands): Schedule of Inventory December 31, December 31, 2022 2021 Raw materials $ 295 $ 178 Work-in-progress 51 88 Finished goods 156 25 Inventory, gross 502 291 Less: Inventory reserve for excess and slow moving inventory - - Total $ 502 $ 291 Inventory is maintained at the Company’s warehouse, an outsourced third-party contract manufacturing vendor, and at Amazon fulfillment centers. The Company builds its contract manufacturing products based on customer orders and immediately ships the products upon completion of the production process.

Property and Equipment, Net

Property and Equipment, Net	12 Months Ended
	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
Property and Equipment, Net	6. Property and Equipment, Net Property and equipment consist of the following ($ in thousands): Schedule of Property and Equipment Useful Life December 31, December 31, (Years) 2022 2021 Machinery and equipment 3 10 $ 973 $ 940 Office furniture and equipment 3 10 59 50 Leasehold improvements 6 228 228 Construction in progress N/A 55 - Property and equipment, gross 1,315 1,218 Less: accumulated depreciation and amortization (594 ) (495 ) Property and equipment, net $ 721 $ 723 Depreciation expense for the year ended December 31, 2022 and 2021 was $ 99 99

Intangible Assets

Intangible Assets	12 Months Ended
	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	7. Intangible Assets The following provides a breakdown of identifiable intangible assets as of December 31, 2022 and 2021 ($ in thousands): Schedule of Breakdown of Identifiable Intangible Assets December 31, December 31, 2022 2021 Product/Technology Related Identifiable intangible assets, gross $ 31 $ 31 Accumulated amortization (26 ) (16 ) Product/Technology related identifiable intangible assets, net 5 15 Marketing Related Customer related intangible asset, gross 17 17 Tradename related intangible asset, gross 7 7 Accumulated amortization (9 ) (6 ) Marketing related identifiable intangible assets, net 15 18 Total identifiable intangible assets, net $ 20 $ 33 In connection with the May 29, 2020 acquisition of Sports Defense, the Company identified intangible assets of $ 55 5.1 13 As of December 31, 2022, the estimated annual amortization expense for each of the next five fiscal years is as follows ($ in thousands): Schedule of Estimated Annual Amortization Expense 2023 $ 8 2024 2 2025 2 2026 2 2027 2 Thereafter 4 Total $ 20

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	12 Months Ended
	Dec. 31, 2022
Payables and Accruals [Abstract]
Accrued Expenses and Other Current Liabilities	8. Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities consist of the following ($ in thousands): Schedule of Accrued Expenses and Other Current Liabilities December 31, December 31, 2022 2021 Salaries, benefits, and incentive compensation $ 56 $ 54 Franchise tax accrual 52 - Other 22 8 Total accrued expenses and other current liabilities $ 130 $ 62

Common Stock

Common Stock	12 Months Ended
	Dec. 31, 2022
Equity [Abstract]
Common Stock	9. Common Stock Share issuances On December 27, 2021, the Company sold an aggregate of 2,585,000 5.50 5.50 . 45 387,750 387,750 387,750 From January 1, 2021 through March 31, 2021, the Company entered into securities purchase agreements with certain accredited investors whereby the Company sold 101,800 2.80 285 At December 31, 2022, the Company has reserved common stock for issuance in relation to the following: Schedule of Reserved Common Stock For Issuance in Relation Share-based compensation plan 524,937 Warrants to purchase common stock 3,637,190 Restricted stock units 90,432

Share-based Compensation

Share-based Compensation	12 Months Ended
	Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]
Share-based Compensation	10. Share-based Compensation The 2019 Plan provides for the granting of incentive stock options, nonqualified stock options, restricted stock, stock appreciation rights (“SARs”), restricted stock units, performance awards, dividend equivalent rights and other awards, which may be granted singly, in combination, or in tandem, and which may be paid in cash, shares of common stock of the Company or a combination of cash and shares of common stock of the Company. The Company initially reserved a total of 57,143 57,143 485,715 485,715 571,429 300,000 871,429 609,687 14,286 The following table contains information about the 2019 Plan as of December 31, 2022: Schedule of Information about Incentive Plan Awards Awards Reserved for Awards Awards Available for Issuance Issued Exercised Grant 2019 Plan (1) 571,429 564,246 7,183 - Awards issued in excess of 2019 Plan - 45,441 - - Total 571,429 609,687 7,183 - (1) includes incentive stock options and restricted stock units discussed below. Incentive stock options On October 1, 2022, the Company appointed Dr. Neil Chesen to the Company’s Scientific Advisory Board and in consideration for his appointment to the board, the Company granted Dr. Chesen an option to purchase up to 65,000 2.00 15,000 50,000 25,000 2.00 37,500 5.50 36 On October 1, 2022, the Company granted Dr. Leonard Nelson an option to purchase up to 30,000 2.00 5,000 25,000 18 10 On October 1, 2022, the Company granted Dr. Leonard Nelson an option to purchase up to 37,500 5.50 36 10 On January 15, 2021, the Company awarded a contractor options to purchase an aggregate of 14,286 2.80 2,857 11,429 On March 8, 2021, the Company granted Dr. Jerome Zeldis, a member of the Company Board, an option to purchase up to 19,048 2.80 On March 8, 2021, the Company appointed Steven Glassman to the Board of Directors to serve for a term expiring at the next annual meeting of stockholders or until his successor is duly elected and qualified. On March 8, 2021 and in consideration for his appointment to the board of directors, the Company granted Mr. Glassman an option to purchase up to 14,286 2.80 On September 2, 2021, the Company appointed Adam Levy, Yaakov Spinrad and Miranda J. Toledano to the Board of Directors to serve for a term expiring at the next annual meeting of stockholders or until their successor is duly elected and qualified. On September 9, 2021 and in consideration for each person’s appointment to the board of directors, the Company granted each of Mr. Levy, Mr. Spinrad, and Ms. Toledano an option to purchase up to 14,286 5.25 The following table summarizes the Company’s incentive stock option activity and related information for the years ended December 31, 2022 and 2021. Schedule of Incentive Stock Option Activity Weighted Weighted Average Average Contractual Number of Exercise Term in Options Price Years Outstanding at January 1, 2021 387,318 $ 1,124418 9.32 Granted 90,478 3.960526 10.00 Exercised (7,183 ) 1.75 — Forfeited — — — Cancelled (28,571 ) 1.40 — Expired (7,103 ) 1.75 — Outstanding at December 31, 2021 434,939 $ 1.678955 8.56 Granted 195,000 $ 3.3461538 10.00 Exercised —- — — Forfeited — — — Cancelled (100,001 ) 1.40000 — Expired (5,001 ) 1.40000 — Outstanding at December 31, 2022 524,937 $ 2.351416 8.38 Exercisable at December 31, 2022 379,937 $ 1.777020 7.86 As of December 31, 2022 and 2021, vested outstanding stock options had $ 124 408 no 18 36 The Company recognizes compensation expense for stock option awards on a straight-line basis over the applicable service period of the award. The service period is generally the vesting period. The following assumptions were used to calculate share-based compensation expense for year ended December 31, 2022 and 2021: Schedule of Assumptions used in Share-based Compensation 2022 2021 Volatility 277.84 % 171.12 183.48 % Risk-free interest rate 4.06 % 0.46 0.86 % Dividend yield 0.0 % 0.0 % Expected term 5.0 5.0 5.75 The Company does not have sufficient historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior. Accordingly, the Company has elected to use the “simplified method” to estimate the expected term of its share-based awards. The simplified method computes the expected term as the sum of the award’s vesting term plus the original contractual term divided by two. Based on the lack of historical data of volatility for the Company’s common stock, the Company based its estimate of expected volatility on a weighted-average of the historical volatility of comparable public companies that manufacture similar products and are similar in size, stage of life cycle, and financial leverage. Restrictive stock awards Effective as of August 1, 2022, the Company granted a restricted stock award of 84,750 shares of the Company’s common stock to certain officers and employees, all of which shares vest in four equal installments on each of January 1, 2023, January 1, 2024, January 1, 2025 and January 1, 2026. Under ASC 718, Compensation-Stock Compensation 84,750 shares granted based on a closing price of the closing price of the Company’s stock at the grant date of the RSU Grant ($ 1.82 per share). Effective as of January 1, 2022, the Company granted a restricted stock award of 11,364 shares of the Company’s common stock to Adam Levy for his service as our Chief Executive Officer pursuant to the terms of his Executive Employment Agreement dated November 4, 2021, all of which shares vested monthly from January 1, 2022 through December 31, 2022. Under ASC 718, the Company has measured the value of the 11,364 shares granted based on the closing price of the Company’s stock at the grant date of the RSU Grant ($ 4.40 per share). On March 8, 2021, the Company granted a restricted stock award of 39,524 39,524 2.10 Schedule of Restricted Stock Units Grant Weighted Average Number of Grant Date Units Fair Value Outstanding at December 31, 2020 39,524 $ 2.10 Granted — — Exercised and converted to common shares (39,524 ) 2.10 Forfeited — — Outstanding at December 31, 2021 — — Granted 96,114 1.61 Exercised and converted to common shares (5,682 ) 4.40 Forfeited — — Outstanding at December 31, 2022 90,432 $ 1.43 Exercisable at December 31, 2022 5,682 $ 4.40 Under ASC 718, the Company has measured the value of its January 2022 award as if it were vested and issued on the grant date with a value of $ 50 4.40 84,750 1.82 Compensation expense will be recognized ratably over the total vesting schedule. The Company will periodically adjust the cumulative compensation expense for forfeited awards. Stock based compensation of $ 89 285 116 Warrants The following table shows a summary of common stock warrants for the years ended December 31, 2022 and 2021. Summary of Common Stock Warrants Weighted Weighted Average Average Number of Exercise Contractual Warrants Price Term in Years Outstanding at December 31, 2020 210,500 $ 0.85938 2.54 Granted 3,426,690 $ 5.42717 4.98 Exercised — — — Forfeited — — — Cancelled — — — Expired — — — Outstanding at December 31, 2021 3,637,190 $ 5.16281 4.63 Granted — — — Exercised — — — Forfeited — — — Cancelled — — — Expired — — — Outstanding at December 31, 2022 3,637,190 $ 5.16281 3.65 Exercisable at December 31, 2022 3,637,190 $ 5.16281 3.65 As of December 31, 2022 and 2021, vested outstanding warrants had $ 114 372

Notes Payable

Notes Payable	12 Months Ended
	Dec. 31, 2022
Debt Disclosure [Abstract]
Notes Payable	11. Notes Payable PPP Loan On April 22, 2020, the Company, entered into a promissory note with PNC Bank, N.A. (“PNC Bank”), which provided for a loan in the amount of $ 147,300 127,400 147,300 127,400 Economic Injury Disaster Loan On May 28, 2020, the Company entered into the standard loan documents required for securing a loan (the “EIDL Loan”) from the SBA under its Economic Injury Disaster Loan (“EIDL”) assistance program in light of the impact of the COVID-19 pandemic on the Company’s business. Pursuant to that certain Loan Authorization and Agreement (the “SBA Loan Agreement”), the principal amount of the EIDL Loan is up to $ 260,500 3.75 1,270 thirty years 8 283 276 The future annual principal amounts and accrued interest to be paid as of December 31, 2022 are as follows: Schedule Of Debt Instruments Amount For the year ending December 31 ($ in thousands): 2023 $ 5 2024 5 2025 5 2026 6 2027 6 Thereafter 256 Total $ 283

Convertible Notes Payable

Convertible Notes Payable	12 Months Ended
	Dec. 31, 2022
Debt Disclosure [Abstract]
Convertible Notes Payable	12. Convertible Notes Payable On December 24, 2020, the Company issued a $ 100 6 2.80 On January 19, 2021, the Company issued a $ 15 1.05 On March 11, 2021, the Company issued Auctus Fund, LLC, a Delaware limited liability company a one-year senior secured convertible promissory note in the principal amount of $1.68 million, which included $180 thousand of interest which was deemed fully earned as of the issuance date (the “Auctus Note”). The Auctus Note was fully repaid (including all principal and interest) on March 15, 2022 with a one-time cash payment of $1.68 million. On September 2, 2021, the Company issued to certain holders one-year subordinated secured convertible promissory notes in the aggregate principal amount of $ 1,814 194 300 17 133 150 1,478

Warrant Liability

Warrant Liability	12 Months Ended
	Dec. 31, 2022
Warrant Liability
Warrant Liability	13.  Warrant Liability On September 2, 2021, March 11, 2021, February 3, 2021, December 24, 2020, March 18, 2020, September 10, 2019, and November 6, 2019, the Company issued 22,019 , 34,285 , 7,429 , 7,286 , 44,286 , 35,714 and 114,286 warrants, respectively, as equity issuance consideration, in connection with a private placement of the Company’s common stock. The warrants entitle the holder to purchase one share of our common stock at an exercise price equal to $ 0.49 to $ 5.25 per share at any time on or after their issuance date and on or prior to the close of business 3 years after the issuance date (the “Termination Date”). The Company determined that these warrants are free standing financial instruments that are legally detachable and separately exercisable from the common stock included in the public share offering. Management also determined that the warrants required classification as a liability pursuant to ASC 815, Derivatives and Hedging On September 6, 2022, the Company agreed to extend the September 10, 2019 and November 6, 2019 warrants an additional six months until March 9, 2023 and May 5, 2023, respectively. The warrants were remeasured as of September 6, 2022 and consequently resulted in a warrant modification expense of $ 57 The warrants outstanding and fair values at each of the respective valuation dates are summarized below: Schedule of Warrant Liability Warrant Liability Warrants Fair Value Fair Value Fair value as of year ended 12/31/2020 201,572 $ 123 Fair value at initial measurement dates 63,733 $ 3.2097 $ 203 Change in fair value of warrant liability (8 ) Fair value as of year ended 12/31/2021 265,305 $ 318 Modification of warrants - $ 57 Change in fair value of warrant liability - (133 ) Fair value as of year ended 12/31/2022 265,305 $ 242 The warrant liabilities are considered Level 3 liabilities on the fair value hierarchy as the determination of fair value includes various assumptions about future activities and the Company’s stock prices and historical volatility of other comparable public companies used as inputs. As of December 31, 2022, none of the warrants have been exercised. The fair value of the warrant liabilities was measured using a Black-Scholes model. Significant inputs into the model at the inception are as follows: Future Estimated Quarterly Warrant Interest Time to Calculated Dividend Black -Scholes Exercise Expiration Stock Rate Volatility Maturity fair value per Assumptions Price Date Price (8) (annual) (9) (annual) (10) (Years) per share share (11) September 2, 2021 (1) $ .0525 September 2, 2026 $ 3.50 0.78 % 182.74 % 5.0 $ 0.3325 $ — March 11, 2021 (2) $ 4.375 5.25 March 11, 2026 $ 3.50 0.17 % 172.54 % 5.0 $ 0.3325 0.0329 $ — February 3, 2021 (3) $ 2.80 February 3, 2024 $ 2.80 0.18 % 171.71 % 3.0 $ 2.417461 $ — December 24, 2020 (4) $ 2.80 December 24, 2023 $ 2.80 0.17 % 172.54 % 3.0 $ 2.422658 $ — March 18, 2020 (5) $ 1.40 March 18, 2023 $ 1.40 0.66 % 137.41 % 3.0 $ 1.075547 $ — September 10, 2019 (6) $ 0.49 September 10, 2022 $ 0.49 1.61 % 139.84 % 3.0 $ 0.38185 $ — November 6, 2019 (7) $ 0.49 November 6, 2022 $ 0.49 1.60 % 138.48 % 3.0 $ 0.38255 $ — Significant inputs into the model at the reporting period measurement dates are as follows: Future Estimated Quarterly Warrant Interest Time to Calculated Dividend Black-Scholes Exercise Expiration Stock Rate Volatility Maturity fair value per Assumptions Price Date Price (8) (annual) (9) (annual) (10) (Years) per share share (11) December 31, 2022 (1) $ .0525 September 2, 2026 $ 1.25 4.22 % 287.87 % 3.68 $ 0.0968371 $ — December 31, 2022 (2) $ 4.375 5.25 March 11, 2026 $ 1.25 4.22 % 288.66 % 3.20 $ 0.096101 0.0957467 $ — December 31, 2022 (3) $ 2.80 February 3, 2024 $ 1.25 4.73 % 352.74 % 1.10 $ 0.0690620 $ — December 31, 2022 (4) $ 2.80 December 24, 2023 $ 1.25 4.73 % 331.00 % 0.98 $ 0.0681813 $ — December 31, 2022 (5) $ 1.40 March 18, 2023 $ 1.25 4.42 % 147.61 % 0.22 $ 0.0296661 $ — December 31, 2022 (6) $ 0.49 September 10, 2022 $ 1.25 4.42 % 137.02 % 0.35 $ 0.0091855 $ — December 31, 2022 (7) $ 0.49 November 6, 2022 $ 1.25 4.42 % 149.27 % 0.18 $ 0.0085006 $ — Future Estimated Quarterly Warrant Interest Time to Calculated Dividend Black-Scholes Exercise Expiration Stock Rate Volatility Maturity fair value per Assumptions Price Date Price (8) (annual) (9) (annual) (10) (Years) per share share (11) December 31, 2021 (1) $ .0525 September 2, 2026 $ 3.50 0.98 % 205.16 % 4.67 $ 0.0968371 $ — December 31, 2021 (2) $ 4.375 5.25 March 11, 2026 $ 3.50 0.98 % 205.16 % 4.19 $ 0.096101 0.0957467 $ — December 31, 2021 (3) $ 2.80 February 3, 2024 $ 2.80 0.28 % 205.16 % 2.09 $ 0.0690620 $ — December 31, 2021 (4) $ 2.80 December 24, 2023 $ 2.80 0.28 % 205.16 % 1.98 $ 0.0681813 $ — December 31, 2021 (5) $ 1.40 March 18, 2023 $ 1.40 0.28 % 205.16 % 1.21 $ 0.0296661 $ — December 31, 2021 (6) $ 0.49 September 10, 2022 $ 0.49 0.09 % 205.16 % 0.69 $ 0.0091855 $ — December 31, 2021 (7) $ 0.49 November 6, 2022 $ 0.49 0.19 % 205.16 % 0.85 $ 0.0085006 $ — (1) Based on the terms provided in the warrant agreement related to the issuance of common stock of on September 2 nd (2) Based on the terms provided in the warrant agreement related to the issuance of common stock of on March 11 th (3) Based on the terms provided in the warrant agreement related to the issuance of common stock of on February 3 rd (4) Based on the terms provided in the warrant agreement related to the issuance of common stock of on December 24 th (5) Based on the terms provided in the warrant agreement related to the issuance of common stock of on March 18 th (6) Based on the terms provided in the warrant agreement related to the issuance of common stock of on September 10 th (7) Based on the terms provided in the warrant agreement related to the issuance of common stock of on November 6 th (8) Based on the observable transaction value of common stock of per the most recent stock issuance financing agreements. (9) Interest rate for U.S. Treasury Bonds, as of the issuance dates and each presented year ended date, as published by the U.S. Federal Reserve. (10) Based on the historical daily volatility of guideline public companies in the healthcare industry and each presented year ended date. (11) Current estimated dividend payments beyond initial four quarters. At a future date, the Company will review the working capital needs and make a final determination of any future dividend payments.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	14. Commitments and Contingencies Litigation The Company may be subject to legal proceedings and claims that arise in the ordinary course of business. Management is not currently aware of any matters that will have a material effect on the financial position, results of operations, or cash flows of the Company.

Concentrations of Risk

Concentrations of Risk	12 Months Ended
	Dec. 31, 2022
Risks and Uncertainties [Abstract]
Concentrations of Risk	15. Concentrations of Risk The Company’s revenues are concentrated in a small group of customers with some individually having more than 10% of total revenues. For the year ended December 31, 2022, the Company had revenue from one customer that approximated 29 40 22 18 Revenues from three customers that exceeded 10% of total revenues for the year ended December 31, 2021 were 15 % and 14 % and 13 %. The Company had three customers with accounts receivable balances approximating 45 20 12 The Company’s financial instruments that are exposed to concentrations of credit risk consist primarily of cash, cash equivalents and marketable securities. Cash balances are maintained principally at major U.S. financial institutions and are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to regulatory limits. Such cash balances are currently in excess of the FDIC insurance limit of $ 250 501 Marketable securities are comprised of U.S. treasury bills with original maturities greater than three months. The Company has not experienced any losses in such accounts. The Company believes it is not exposed to any significant credit risk on cash, cash equivalents, and marketable securities and performs periodic evaluations of the credit standing of such institutions.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2022
Related Party Transactions [Abstract]
Related Party Transactions	16. Related Party Transactions Convertible Promissory Note On December 24, 2020, the Company issued two 100,000 On September 2, 2021, the Company issued three 150,000 150,000 50,000 Advances Dr. Jerome Zeldis, a member of the Company board of directors, has an outstanding balance due of $ 40,000

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Income Taxes	17. Income Taxes The Company has established a full valuation allowance for its deferred tax assets based on management’s belief that it is not more likely than not that the related deferred tax assets will be realized. For the years ended December 31, 2022 and 2021, there was no At December 31, 2022 and 2021, the Company had no The income tax (benefit) provision consists of the following: Schedule of income tax (benefit) provision 2022 2021 For The Years Ended December 31 2022 2021 Federal: Current $ — $ — Deferred — — State and local: Current — — Deferred — — Income tax provision $ — $ — For the years ended December 31, 2022 and 2021, the expected tax benefit based on the statutory rate reconciled with the actual benefit is as follows: Schedule of Effective Income Tax Rate Reconciliation For The Years Ended December 31, 2022 2021 U.S. federal statutory rate 21.0 % 21.0 % State tax rate, net of federal benefit 5.3 % 5.3 % Permanent differences Non-deductible expenses (9.7 )% (10.5 )% Timing differences (0.0 )% 0.6 % Change in valuation allowance (16.6 )% (16.4 )% Income tax provision 0.0 % 0.0 % For the years ended December 31, 2022 and 2021, differences between the expected tax expense based on the federal statutory rate and the actual tax expense is primarily attributable to the net losses incurred and the corresponding increase to the valuation allowance. As of December 31, 2022 and 2021, the Company’s deferred tax assets consisted of the effects of temporary differences attributable to the following: Schedule of Deferred Tax Assets and Liabilities As of December 31, 2022 2021 Deferred tax assets: Net operating loss carryforwards $ 4,112 $ 3,326 Other 6 4 Total deferred tax assets 4,118 3,330 Valuation allowance (4,118 ) (3,330 ) Deferred tax assets, net of valuation allowance $ — $ — Deferred tax liabilities: Property and equipment, net — — Total deferred tax liabilities — — Net deferred tax liabilities $ — $ — As of December 31, 2022 and 2021, the Company has approximately $ 15.6 12.6 15.6 12.6 In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will be realized. The ultimate realization of the deferred tax assets is dependent upon the future generation of taxable income during the years in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. After consideration of all the evidence, both positive and negative, management has recorded a full valuation allowance against net deferred tax assets at December 31, 2022 and 2021 because management has determined that it is more likely than not that these deferred tax assets will not be realized. The Company is subject to taxation in the U.S. and various states. Based on the history of net operating losses all jurisdictions and tax years are open for examination until the operating losses are utilized or the statute of limitations expires. As of December 31, 2022 and 2021, the Company does not have any significant uncertain tax positions.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2022
Subsequent Events [Abstract]
Subsequent Events	18. Subsequent Events Management of the Company has performed a review of events and transactions occurring after the consolidated balance sheet date to determine if there were any such events or transactions requiring adjustment to or disclosure in the accompanying consolidated financial statements, noting no such events other than the following. On January 16, 2023, Scott R. Henry was appointed to the board of directors of the Company to serve for a term expiring at the Company’s next annual meeting of stockholders or his successor is duly elected and qualified. Mr. Henry was also appointed as a member to the Audit Committee of the board of directors. On March 1, 2023, the Company acquired a 50% 50% 50% 500,000 On March 21, 2023, the Company entered into a Services Agreement with GlaxoSmithKline Consumer Healthcare Holdings (US) LLC (“Haleon”) to supply material for a consumer product to be developed and released in the future. There can be no guaranty that a consumer product will be released or, if released, that it will be successful. GlaxoSmithKline Consumer Healthcare Holdings (US) LLC is a Haleon group company. On March 23, 2023, the board of directors of the Company approved an increase of the number of shares to be reserved under the Company’s 2019 Long-Term Incentive Plan by 300,000 571,429 871,429

Significant Accounting Polici_2

Significant Accounting Policies and Estimates (Policies)	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Use of Estimates	Use of Estimates The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. These estimates and assumptions include allowances for doubtful accounts, inventory reserves, deferred taxes, share-based compensation and related valuation allowances and fair value of long-lived assets. Actual results could differ from the estimates.
Reclassifications	Reclassifications We have reclassified, combined or separately disclosed certain amounts in the prior years’ consolidated financial statements and accompanying footnotes to conform with the current year’s presentation.
Cash	Cash Cash is comprised of cash in banks and highly liquid investments, including U.S. treasury bills purchased with an original maturity of three months or less as well as investments in money market funds for which the carrying amount approximates fair value, due to the short maturities of these investments.
Marketable Securities	Marketable Securities The Company classifies its marketable securities as held-to-maturity, which include U.S. treasury bills with original maturities of greater than three months. These securities are carried at fair value with any change in fair value recorded as an unrealized gain (loss) in the statement of operations of the year in which such change occurs. The total unrealized gain related to the marketable securities was inconsequential during the year ended December 31, 2022. The Company had no marketable securities as of December 31, 2021. Schedule of Marketable Securities December 31, 2022 Marketable Securities United States treasury bills (due February 23, 2023) $ 492 United States treasury bills (due April 27, 2023) 20 United States treasury bills (due June 15, 2023) 4,384 United States treasury bills (due July 13, 2023) 127 United States treasury bills (due August 10, 2023) 485 Total $ 5,508
Accounts Receivable, net	Accounts Receivable, net Trade accounts receivable are stated at the amount the Company expects to collect and do not bear interest. The Company evaluates the collectability of accounts receivable and records a provision to the allowance for doubtful accounts based on factors including the length of time the receivables are past due, the current business environment and the Company’s historical experience. Provisions to the allowances for doubtful accounts are recorded in selling, general and administrative expenses. Account balances are charged off against the allowance when it is probable that the receivable will not be recovered. The allowance for doubtful accounts was $ 9 4
Inventory and Cost of Revenues	Inventory and Cost of Revenues Inventory is stated at the lower of cost, the value determined by the first-in, first-out method, or net realizable value. The Company evaluates inventories for excess quantities, obsolescence, and shelf-life expiration. This evaluation includes an analysis of historical sales levels by product, projections of future demand, the risk of technological or competitive obsolescence for products, general market conditions, and a review of the shelf-life expiration dates for products. These factors determine when, and if, the Company adjusts the carrying value of inventory to estimated net realizable value. The Company produces proprietary branded products and white label opportunities in our manufacturing of consumer products. In our contract manufacturing, the Company builds its products based on customer orders and immediately ships the products upon completion of the production process. The balance is made up of raw materials, work-in-progress, and finished goods of $ 295 51 156 178 88 25 The “Cost of revenues” line item in the consolidated statements of operations is comprised of the book value of inventory sold to customers during the reporting period. When circumstances dictate that we use net realizable value as the basis for recording inventory, we base our estimates on expected future selling prices less expected disposal costs.
Research and Development	Research and Development Our research and development activities focus on new and innovative products designed to support revenue growth. Research and development expenses consist primarily of contracted development and testing efforts associated with development of products.
Shipping and Handling Revenue and Expense	Shipping and Handling Revenue and Expense Shipping and handling revenue and expense are included in our consolidated statements of operations in revenues and cost of revenues, respectively. This is primarily through shipping fees incurred in the Amazon marketplace.
Property and Equipment, net	Property and Equipment, net Property and equipment is recorded at historical cost, net of accumulated depreciation and amortization. Depreciation is provided over the assets’ useful lives on a straight-line basis. Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or lease terms. Repairs and maintenance costs are expensed as incurred. Management periodically assesses the estimated useful life over which assets are depreciated or amortized. If the analysis warrants a change in the estimated useful life of property and equipment, management will reduce the estimated useful life and depreciate or amortize the carrying value prospectively over the shorter remaining useful life. The carrying amounts of assets sold or retired and the related accumulated depreciation are eliminated in the year of disposal and any resulting gains and losses are included in the results of operations during the same year.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets The Company reviews its property and equipment and any identifiable intangibles for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted operating cash flow expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value of the asset. Long-lived assets to be disposed of are reported at the lower of carrying amount or fair value less costs to sell.
Goodwill and Intangible Assets	Goodwill and Intangible Assets In applying the acquisition method of accounting, amounts assigned to identifiable assets and liabilities acquired were based on estimated fair values as of the date of acquisition, with the remainder recorded as goodwill. Identifiable intangible assets are initially recorded at fair value using generally accepted valuation methods appropriate for the type of intangible asset. Identifiable intangible assets with definite lives are amortized over their estimated useful lives and are reviewed for impairment if indicators of impairment arise. Intangible assets with indefinite lives are tested for impairment within one year of acquisitions or annually as of December 31, and whenever indicators of impairment exist. The fair value of intangible assets is compared with their carrying values, and an impairment loss would be recognized for the amount by which a carrying amount exceeds its fair value. The Company performed the annual assessment and concluded it is more likely than not that the fair value exceeds the carrying value and no
Prepaid Expenses and Other Current Assets	Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets are recorded at historical cost and is primarily made up of $ 63 23 109 54
Other Assets	Other Assets Other Assets is recorded at historical costs, and as of December 31, 2022 and 2021, the balance is primarily comprised of spare parts for manufacturing equipment. Other assets are stated at cost and are not subject to depreciation, until such time that they are placed into service and the part that is being replaced is disposed.
Fair Value Measurements	Fair Value Measurements The Company utilizes the fair value hierarchy to apply fair value measurements. The fair value hierarchy is based on inputs to valuation techniques that are used to measure fair values that are either observable or unobservable. Observable inputs reflect assumptions market participants would use in pricing an asset or liability based on market data obtained from independent sources, while unobservable inputs reflect a reporting entity’s pricing based upon its own market assumptions. The basis for fair value measurements for each level within the hierarchy is described below: Level 1 Level 2 Level 3 The Company considers the carrying amounts of its financial instruments (cash, accounts receivable and accounts payable) in the balance sheet to approximate fair value because of the short-term or highly liquid nature of these financial instruments. The following table sets forth the fair value of the Company’s financial assets within the fair value hierarchy: Schedule of Fair Value of Financial Assets Level 1 Level 2 Level 3 Fair Value December 31, 2022 Level 1 Level 2 Level 3 Fair Value Assets Marketable securities: United States treasury bills $ 5,508 $ - $ - $ 5,508 Total $ 5,508 $ - $ - $ 5,508
Warrant Liability	Warrant Liability Warrants to purchase common stock were issued in connection with equity financing raises, which occurred during 2019 through 2021. The fair values of the warrants are estimated as of the date of issuance and again at each year end using a Black-Scholes option valuation model. At issuance, the fair values of the warrant are recognized as an equity issuance cost within additional paid-in-capital. Fair value adjustments to the warrant liability are recognized in other income (expense) in the statements of operations.
Revenue Recognition	Revenue Recognition On January 1, 2018, the Company adopted Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers The Company currently recognizes revenue predominately from three types of revenue, contract manufacturing, custom and white label finished goods manufacturing and our branded products. Revenues from manufactured products are recognized at the point where the customer obtains control of the goods and the Company satisfies its performance obligation, which generally is at the time the customer receives the product. The Company’s customers consist of other life sciences companies and Amazon retail customers. Revenues are entirely concentrated in the United States. Payment terms vary by the type and location of customer and may differ by jurisdiction and customer but payment is generally required in a term ranging from 30 to 60 days from date of shipment. Estimates for product returns, allowances and discounts are recorded as a reduction of revenue and are established at the time of sale. Returns are estimated through a comparison of historical return data and are determined for each product and adjusted for known or expected changes in the marketplace specific to each product, when appropriate. Historically, sales return provisions have not been material. Amounts accrued for sales allowances and discounts are based on estimates of amounts that are expected to be claimed on the related sales and are based on historical data. Payments for allowances and discounts have historically been immaterial. Disaggregated revenue by sales type: Schedule of Disaggregated Revenue by Sales Type 2022 2021 Year Ended December 31, 2022 2021 Contract manufacturing $ 1,033 $ 767 Custom and white label finished goods manufacturing 34 194 NexGel branded consumer products 815 488 Other 166 102 Total $ 2,048 $ 1,551 As of December 31, 2022 and 2021, the Company did not have any contract assets or contract liabilities from contracts with customers and there were no The Company has four distinct lines of business; Contract Manufacturing, Custom & White Label, Consumer Branded Products, and Medical Devices. Contract Manufacturing Customers order rolls of gel (“rollstock”). The rollstock is shipped to our customers, which they package into finished goods. Historically, this has been the Company’s primary source of revenue. Custom & White Label These products often infuse various ingredients into our base gel to develop unique product offerings to satisfy market demand (e.g. aloe infused into the gel for a beauty mask). The rollstock is converted and packaged into salable units. The finished goods are shipped to the customer, who is ultimately responsible for product distribution. Frequently these products started as development deals, in which the customer paid the Company a small fee to develop a specific product. Once completed, the customer places a large order for newly developed product. Consumer Branded Products These products are finished goods marketed and sold directly to the customer by the Company through online and retail channels. The Company is responsible for sales, marketing, and distribution. These products carry the Company’s brand names. Medical Devices Medical Devices are a hybrid business, combining elements of Custom & White Label and Consumer Branded Products. Medical Devices, which are not yet marketed, are expected to be distributed through strategic partnerships. The Company will manufacture and possibly convert/package the device while the strategic partner brings the product to market. Small market Medical Devices could be launched by the Company, but also be offered to a distributor to reach the full scale of the market.
Share-based Compensation	Share-based Compensation On August 28, 2019, the Company adopted the 2019 Long-Term Incentive Plan, as amended (the “2019 Plan”). See Note 10 and note 18 below for further details regarding the 2019 Plan. The 2019 Plan provides certain employees, contractors, and outside directors with share-based compensation in the form of incentive stock options, nonqualified stock options, stock appreciation rights, restricted stock, restricted stock units, performance awards, dividend equivalent rights and other awards. The fair values of incentive stock option award grants are estimated as of the date of grant using a Black-Scholes option valuation model. Compensation expense is recognized in the statements of operations on a straight-line basis over the requisite service period, which is generally the vesting period required to obtain full vesting. Forfeitures are accounted for when they occur. In June 2018, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2018-07, Compensation - Stock Compensation (Topic 718) - Improvements to Nonemployee Share-Based Payment Accounting Compensation - Stock Compensation
Income Taxes	Income Taxes Income taxes are accounted for using an asset and liability approach that requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the financial statement and tax bases of assets and liabilities at the applicable tax rates. Deferred tax assets are reduced by a valuation allowance when it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates. Tax benefits are recognized from an uncertain tax position only if it is more likely than not that the tax position will be sustained upon examination by a tax authority and based upon the technical merits of the tax position. The tax benefit recognized in the consolidated financial statements for a particular tax position is based on the largest benefit that is more likely than not to be realized upon settlement. An unrecognized tax benefit, or a portion thereof, is presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward if such settlement is required or expected in the event the uncertain tax position is disallowed.
Leases	Leases ASC 842 requires recognition of leases on the consolidated balance sheets as right-of-use (“ROU”) assets and lease liabilities. ROU assets represent the Company’s right to use underlying assets for the lease terms and lease liabilities represent the Company’s obligation to make lease payments arising from the leases. Operating lease ROU assets and operating lease liabilities are recognized based on the present value and future minimum lease payments over the lease term at commencement date. As the Company’s leases do not provide an implicit rate, the Company used its estimated incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. A number of the lease agreements contain options to renew and options to terminate the leases early. The lease term used to calculate ROU assets and lease liabilities only includes renewal and termination options that are deemed reasonably certain to be exercised. The Company recognized lease liabilities, with corresponding ROU assets, based on the present value of unpaid lease payments for existing operating leases longer than twelve months. The ROU assets were adjusted per ASC 842 transition guidance for existing lease-related balances of accrued and prepaid rent, and unamortized lease incentives provided by lessors. Operating lease cost is recognized as a single lease cost on a straight-line basis over the lease term and is recorded in selling, general and administrative expenses. Variable lease payments for common area maintenance, property taxes and other operating expenses are recognized as expense in the year when the changes in facts and circumstances on which the variable lease payments are based occur. The Company has elected not to separate lease and non-lease components for all property leases for the purposes of calculating ROU assets and lease liabilities.
Segment reporting	Segment reporting The Company operates in one
Comprehensive loss	Comprehensive loss Comprehensive loss consists of net loss and changes in equity during a year from transactions and other equity and circumstances generated from non-owner sources. The Company’s net loss equals comprehensive loss for all years presented,
Recently Issued Accounting Standards	Recently Issued Accounting Standards From time to time, new accounting pronouncements are issued by the FASB, or other standard setting bodies and adopted by us as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on our consolidated financial position or results of operations upon adoption. In June 2016, FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments In January 2017, the FASB issued ASU 2017-04, Intangibles—Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes

Significant Accounting Polici_3

Significant Accounting Policies and Estimates (Tables)	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Schedule of Marketable Securities	Schedule of Marketable Securities December 31, 2022 Marketable Securities United States treasury bills (due February 23, 2023) $ 492 United States treasury bills (due April 27, 2023) 20 United States treasury bills (due June 15, 2023) 4,384 United States treasury bills (due July 13, 2023) 127 United States treasury bills (due August 10, 2023) 485 Total $ 5,508
Schedule of Fair Value of Financial Assets	The following table sets forth the fair value of the Company’s financial assets within the fair value hierarchy: Schedule of Fair Value of Financial Assets Level 1 Level 2 Level 3 Fair Value December 31, 2022 Level 1 Level 2 Level 3 Fair Value Assets Marketable securities: United States treasury bills $ 5,508 $ - $ - $ 5,508 Total $ 5,508 $ - $ - $ 5,508
Schedule of Disaggregated Revenue by Sales Type	Disaggregated revenue by sales type: Schedule of Disaggregated Revenue by Sales Type 2022 2021 Year Ended December 31, 2022 2021 Contract manufacturing $ 1,033 $ 767 Custom and white label finished goods manufacturing 34 194 NexGel branded consumer products 815 488 Other 166 102 Total $ 2,048 $ 1,551

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2022
Leases
Schedule of Future Minimum Lease Payments	The following table presents information about the amount and timing of the liability arising from the Company’s operating lease as of December 31, 2022 ($ in thousands): Schedule of Future Minimum Lease Payments Maturity of Lease Liability Operating 2023 $ 207 2024 207 2025 207 2026 263 2027 274 Thereafter 890 Total undiscounted operating lease payments $ 2,048 Less: Imputed interest (248 ) Present value of operating lease liability $ 1,800 Weighted average remaining lease term 8.1 Weighted average discount rate 3.0 %
Schedule of Supplemental Cash Flows Information Related to Leases	Supplemental cash flows information related to leases was as follows ($ in thousands): Schedule of Supplemental Cash Flows Information Related to Leases December 31, 2022 Cash paid for amounts included in the measurement of lease liability: Operating cash flows from operating lease $ 207

Inventory (Tables)

Inventory (Tables)	12 Months Ended
	Dec. 31, 2022
Inventory Disclosure [Abstract]
Schedule of Inventory	Inventory consists of the following ($ in thousands): Schedule of Inventory December 31, December 31, 2022 2021 Raw materials $ 295 $ 178 Work-in-progress 51 88 Finished goods 156 25 Inventory, gross 502 291 Less: Inventory reserve for excess and slow moving inventory - - Total $ 502 $ 291

Property and Equipment, Net (Ta

Property and Equipment, Net (Tables)	12 Months Ended
	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	Property and equipment consist of the following ($ in thousands): Schedule of Property and Equipment Useful Life December 31, December 31, (Years) 2022 2021 Machinery and equipment 3 10 $ 973 $ 940 Office furniture and equipment 3 10 59 50 Leasehold improvements 6 228 228 Construction in progress N/A 55 - Property and equipment, gross 1,315 1,218 Less: accumulated depreciation and amortization (594 ) (495 ) Property and equipment, net $ 721 $ 723

Intangible Assets (Tables)

Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Breakdown of Identifiable Intangible Assets	The following provides a breakdown of identifiable intangible assets as of December 31, 2022 and 2021 ($ in thousands): Schedule of Breakdown of Identifiable Intangible Assets December 31, December 31, 2022 2021 Product/Technology Related Identifiable intangible assets, gross $ 31 $ 31 Accumulated amortization (26 ) (16 ) Product/Technology related identifiable intangible assets, net 5 15 Marketing Related Customer related intangible asset, gross 17 17 Tradename related intangible asset, gross 7 7 Accumulated amortization (9 ) (6 ) Marketing related identifiable intangible assets, net 15 18 Total identifiable intangible assets, net $ 20 $ 33
Schedule of Estimated Annual Amortization Expense	As of December 31, 2022, the estimated annual amortization expense for each of the next five fiscal years is as follows ($ in thousands): Schedule of Estimated Annual Amortization Expense 2023 $ 8 2024 2 2025 2 2026 2 2027 2 Thereafter 4 Total $ 20

Accrued Expenses and Other Cu_2

Accrued Expenses and Other Current Liabilities (Tables)	12 Months Ended
	Dec. 31, 2022
Payables and Accruals [Abstract]
Schedule of Accrued Expenses and Other Current Liabilities	Accrued expenses and other current liabilities consist of the following ($ in thousands): Schedule of Accrued Expenses and Other Current Liabilities December 31, December 31, 2022 2021 Salaries, benefits, and incentive compensation $ 56 $ 54 Franchise tax accrual 52 - Other 22 8 Total accrued expenses and other current liabilities $ 130 $ 62

Common Stock (Tables)

Common Stock (Tables)	12 Months Ended
	Dec. 31, 2022
Equity [Abstract]
Schedule of Reserved Common Stock For Issuance in Relation	At December 31, 2022, the Company has reserved common stock for issuance in relation to the following: Schedule of Reserved Common Stock For Issuance in Relation Share-based compensation plan 524,937 Warrants to purchase common stock 3,637,190 Restricted stock units 90,432

Share-based Compensation (Table

Share-based Compensation (Tables)	12 Months Ended
	Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]
Schedule of Information about Incentive Plan	The following table contains information about the 2019 Plan as of December 31, 2022: Schedule of Information about Incentive Plan Awards Awards Reserved for Awards Awards Available for Issuance Issued Exercised Grant 2019 Plan (1) 571,429 564,246 7,183 - Awards issued in excess of 2019 Plan - 45,441 - - Total 571,429 609,687 7,183 - (1) includes incentive stock options and restricted stock units discussed below.
Schedule of Incentive Stock Option Activity	The following table summarizes the Company’s incentive stock option activity and related information for the years ended December 31, 2022 and 2021. Schedule of Incentive Stock Option Activity Weighted Weighted Average Average Contractual Number of Exercise Term in Options Price Years Outstanding at January 1, 2021 387,318 $ 1,124418 9.32 Granted 90,478 3.960526 10.00 Exercised (7,183 ) 1.75 — Forfeited — — — Cancelled (28,571 ) 1.40 — Expired (7,103 ) 1.75 — Outstanding at December 31, 2021 434,939 $ 1.678955 8.56 Granted 195,000 $ 3.3461538 10.00 Exercised —- — — Forfeited — — — Cancelled (100,001 ) 1.40000 — Expired (5,001 ) 1.40000 — Outstanding at December 31, 2022 524,937 $ 2.351416 8.38 Exercisable at December 31, 2022 379,937 $ 1.777020 7.86
Schedule of Assumptions used in Share-based Compensation	Schedule of Assumptions used in Share-based Compensation 2022 2021 Volatility 277.84 % 171.12 183.48 % Risk-free interest rate 4.06 % 0.46 0.86 % Dividend yield 0.0 % 0.0 % Expected term 5.0 5.0 5.75
Schedule of Restricted Stock Units Grant	Schedule of Restricted Stock Units Grant Weighted Average Number of Grant Date Units Fair Value Outstanding at December 31, 2020 39,524 $ 2.10 Granted — — Exercised and converted to common shares (39,524 ) 2.10 Forfeited — — Outstanding at December 31, 2021 — — Granted 96,114 1.61 Exercised and converted to common shares (5,682 ) 4.40 Forfeited — — Outstanding at December 31, 2022 90,432 $ 1.43 Exercisable at December 31, 2022 5,682 $ 4.40
Summary of Common Stock Warrants	The following table shows a summary of common stock warrants for the years ended December 31, 2022 and 2021. Summary of Common Stock Warrants Weighted Weighted Average Average Number of Exercise Contractual Warrants Price Term in Years Outstanding at December 31, 2020 210,500 $ 0.85938 2.54 Granted 3,426,690 $ 5.42717 4.98 Exercised — — — Forfeited — — — Cancelled — — — Expired — — — Outstanding at December 31, 2021 3,637,190 $ 5.16281 4.63 Granted — — — Exercised — — — Forfeited — — — Cancelled — — — Expired — — — Outstanding at December 31, 2022 3,637,190 $ 5.16281 3.65 Exercisable at December 31, 2022 3,637,190 $ 5.16281 3.65

Notes Payable (Tables)

Notes Payable (Tables)	12 Months Ended
	Dec. 31, 2022
Debt Disclosure [Abstract]
Schedule Of Debt Instruments	The future annual principal amounts and accrued interest to be paid as of December 31, 2022 are as follows: Schedule Of Debt Instruments Amount For the year ending December 31 ($ in thousands): 2023 $ 5 2024 5 2025 5 2026 6 2027 6 Thereafter 256 Total $ 283

Warrant Liability (Tables)

Warrant Liability (Tables)	12 Months Ended
	Dec. 31, 2022
Warrant Liability
Schedule of Warrant Liability	The warrants outstanding and fair values at each of the respective valuation dates are summarized below: Schedule of Warrant Liability Warrant Liability Warrants Fair Value Fair Value Fair value as of year ended 12/31/2020 201,572 $ 123 Fair value at initial measurement dates 63,733 $ 3.2097 $ 203 Change in fair value of warrant liability (8 ) Fair value as of year ended 12/31/2021 265,305 $ 318 Modification of warrants - $ 57 Change in fair value of warrant liability - (133 ) Fair value as of year ended 12/31/2022 265,305 $ 242 The warrant liabilities are considered Level 3 liabilities on the fair value hierarchy as the determination of fair value includes various assumptions about future activities and the Company’s stock prices and historical volatility of other comparable public companies used as inputs. As of December 31, 2022, none of the warrants have been exercised. The fair value of the warrant liabilities was measured using a Black-Scholes model. Significant inputs into the model at the inception are as follows: Future Estimated Quarterly Warrant Interest Time to Calculated Dividend Black -Scholes Exercise Expiration Stock Rate Volatility Maturity fair value per Assumptions Price Date Price (8) (annual) (9) (annual) (10) (Years) per share share (11) September 2, 2021 (1) $ .0525 September 2, 2026 $ 3.50 0.78 % 182.74 % 5.0 $ 0.3325 $ — March 11, 2021 (2) $ 4.375 5.25 March 11, 2026 $ 3.50 0.17 % 172.54 % 5.0 $ 0.3325 0.0329 $ — February 3, 2021 (3) $ 2.80 February 3, 2024 $ 2.80 0.18 % 171.71 % 3.0 $ 2.417461 $ — December 24, 2020 (4) $ 2.80 December 24, 2023 $ 2.80 0.17 % 172.54 % 3.0 $ 2.422658 $ — March 18, 2020 (5) $ 1.40 March 18, 2023 $ 1.40 0.66 % 137.41 % 3.0 $ 1.075547 $ — September 10, 2019 (6) $ 0.49 September 10, 2022 $ 0.49 1.61 % 139.84 % 3.0 $ 0.38185 $ — November 6, 2019 (7) $ 0.49 November 6, 2022 $ 0.49 1.60 % 138.48 % 3.0 $ 0.38255 $ — Significant inputs into the model at the reporting period measurement dates are as follows: Future Estimated Quarterly Warrant Interest Time to Calculated Dividend Black-Scholes Exercise Expiration Stock Rate Volatility Maturity fair value per Assumptions Price Date Price (8) (annual) (9) (annual) (10) (Years) per share share (11) December 31, 2022 (1) $ .0525 September 2, 2026 $ 1.25 4.22 % 287.87 % 3.68 $ 0.0968371 $ — December 31, 2022 (2) $ 4.375 5.25 March 11, 2026 $ 1.25 4.22 % 288.66 % 3.20 $ 0.096101 0.0957467 $ — December 31, 2022 (3) $ 2.80 February 3, 2024 $ 1.25 4.73 % 352.74 % 1.10 $ 0.0690620 $ — December 31, 2022 (4) $ 2.80 December 24, 2023 $ 1.25 4.73 % 331.00 % 0.98 $ 0.0681813 $ — December 31, 2022 (5) $ 1.40 March 18, 2023 $ 1.25 4.42 % 147.61 % 0.22 $ 0.0296661 $ — December 31, 2022 (6) $ 0.49 September 10, 2022 $ 1.25 4.42 % 137.02 % 0.35 $ 0.0091855 $ — December 31, 2022 (7) $ 0.49 November 6, 2022 $ 1.25 4.42 % 149.27 % 0.18 $ 0.0085006 $ — Future Estimated Quarterly Warrant Interest Time to Calculated Dividend Black-Scholes Exercise Expiration Stock Rate Volatility Maturity fair value per Assumptions Price Date Price (8) (annual) (9) (annual) (10) (Years) per share share (11) December 31, 2021 (1) $ .0525 September 2, 2026 $ 3.50 0.98 % 205.16 % 4.67 $ 0.0968371 $ — December 31, 2021 (2) $ 4.375 5.25 March 11, 2026 $ 3.50 0.98 % 205.16 % 4.19 $ 0.096101 0.0957467 $ — December 31, 2021 (3) $ 2.80 February 3, 2024 $ 2.80 0.28 % 205.16 % 2.09 $ 0.0690620 $ — December 31, 2021 (4) $ 2.80 December 24, 2023 $ 2.80 0.28 % 205.16 % 1.98 $ 0.0681813 $ — December 31, 2021 (5) $ 1.40 March 18, 2023 $ 1.40 0.28 % 205.16 % 1.21 $ 0.0296661 $ — December 31, 2021 (6) $ 0.49 September 10, 2022 $ 0.49 0.09 % 205.16 % 0.69 $ 0.0091855 $ — December 31, 2021 (7) $ 0.49 November 6, 2022 $ 0.49 0.19 % 205.16 % 0.85 $ 0.0085006 $ — (1) Based on the terms provided in the warrant agreement related to the issuance of common stock of on September 2 nd (2) Based on the terms provided in the warrant agreement related to the issuance of common stock of on March 11 th (3) Based on the terms provided in the warrant agreement related to the issuance of common stock of on February 3 rd (4) Based on the terms provided in the warrant agreement related to the issuance of common stock of on December 24 th (5) Based on the terms provided in the warrant agreement related to the issuance of common stock of on March 18 th (6) Based on the terms provided in the warrant agreement related to the issuance of common stock of on September 10 th (7) Based on the terms provided in the warrant agreement related to the issuance of common stock of on November 6 th (8) Based on the observable transaction value of common stock of per the most recent stock issuance financing agreements. (9) Interest rate for U.S. Treasury Bonds, as of the issuance dates and each presented year ended date, as published by the U.S. Federal Reserve. (10) Based on the historical daily volatility of guideline public companies in the healthcare industry and each presented year ended date. (11) Current estimated dividend payments beyond initial four quarters. At a future date, the Company will review the working capital needs and make a final determination of any future dividend payments.

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Schedule of income tax (benefit) provision	The income tax (benefit) provision consists of the following: Schedule of income tax (benefit) provision 2022 2021 For The Years Ended December 31 2022 2021 Federal: Current $ — $ — Deferred — — State and local: Current — — Deferred — — Income tax provision $ — $ —
Schedule of Effective Income Tax Rate Reconciliation	For the years ended December 31, 2022 and 2021, the expected tax benefit based on the statutory rate reconciled with the actual benefit is as follows: Schedule of Effective Income Tax Rate Reconciliation For The Years Ended December 31, 2022 2021 U.S. federal statutory rate 21.0 % 21.0 % State tax rate, net of federal benefit 5.3 % 5.3 % Permanent differences Non-deductible expenses (9.7 )% (10.5 )% Timing differences (0.0 )% 0.6 % Change in valuation allowance (16.6 )% (16.4 )% Income tax provision 0.0 % 0.0 %
Schedule of Deferred Tax Assets and Liabilities	As of December 31, 2022 and 2021, the Company’s deferred tax assets consisted of the effects of temporary differences attributable to the following: Schedule of Deferred Tax Assets and Liabilities As of December 31, 2022 2021 Deferred tax assets: Net operating loss carryforwards $ 4,112 $ 3,326 Other 6 4 Total deferred tax assets 4,118 3,330 Valuation allowance (4,118 ) (3,330 ) Deferred tax assets, net of valuation allowance $ — $ — Deferred tax liabilities: Property and equipment, net — — Total deferred tax liabilities — — Net deferred tax liabilities $ — $ —

Description of Business, Stoc_2

Description of Business, Stock Split and Basis of Presentation (Details Narrative) - $ / shares	Nov. 29, 2021	Dec. 31, 2022	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Reverse stock split	1-for-35 reverse stock split
Common stock, par value	$ 0.001	$ 0.001	$ 0.001

Going Concern (Details Narrativ

Going Concern (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands		12 Months Ended
	Dec. 27, 2021	Dec. 31, 2022	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash		$ 1,101	$ 13,350
Marketable securities		5,508
Net loss		4,746	4,310
Net cash used in operating activities		2,992	$ 2,753
Working capital		$ 6,600
Number of units sold	2,585,000
Purchase price, per unit	$ 5.50
Exercise price	$ 5.50
Proceeds from warrants exercise	$ 14,200

Schedule of Marketable Securiti

Schedule of Marketable Securities (Details) $ in Thousands	Dec. 31, 2022 USD ($)
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Total	$ 5,508
US Treasury Securities [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Total	5,508
US Treasury Securities [Member] | Februrary Twenty ThreeTwo Thousand And Twenty Three [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Total	492
US Treasury Securities [Member] | April Twenty Seven Two Thousand And Twenty Three [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Total	20
US Treasury Securities [Member] | June Fifteen Two Thousand And Twenty Three [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Total	4,384
US Treasury Securities [Member] | July Thirteen Two Thousand Twenty Three [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Total	127
US Treasury Securities [Member] | August Ten Two Thousand Twenty Three [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Total	$ 485

Schedule of Fair Value of Finan

Schedule of Fair Value of Financial Assets (Details) $ in Thousands	Dec. 31, 2022 USD ($)
Defined Benefit Plan Disclosure [Line Items]
Total	$ 5,508
US Treasury Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Total	5,508
Fair Value, Inputs, Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Total	5,508
Fair Value, Inputs, Level 1 [Member] | US Treasury Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Total	5,508
Fair Value, Inputs, Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Total
Fair Value, Inputs, Level 2 [Member] | US Treasury Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Total
Fair Value, Inputs, Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Total
Fair Value, Inputs, Level 3 [Member] | US Treasury Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Total

Schedule of Disaggregated Reven

Schedule of Disaggregated Revenue by Sales Type (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Accounting Policies [Abstract]
Contract manufacturing	$ 1,033	$ 767
Custom and white label finished goods manufacturing	34	194
NexGel branded consumer products	815	488
Other	166	102
Total	$ 2,048	$ 1,551

Significant Accounting Polici_4

Significant Accounting Policies and Estimates (Details Narrative)	12 Months Ended
	Dec. 31, 2022 USD ($) Segment	Dec. 31, 2021 USD ($)
Accounting Policies [Abstract]
Allowance for doubtful accounts	$ 9,000	$ 4,000
Raw materials	295,000	178,000
Work-in-progress	51,000	88,000
Finished goods	156,000	25,000
Asset impairment charges	0	0
Prepaid insurance	63,000	23,000
General prepaid expenses	109,000	54,000
Remaining performance obligations	$ 0	$ 0
Number of Operating Segments | Segment	1

Schedule of Future Minimum Leas

Schedule of Future Minimum Lease Payments (Details) $ in Thousands	Dec. 31, 2022 USD ($)
Maturity of Lease Liability
2023	$ 207
2024	207
2025	207
2026	263
2027	274
Thereafter	890
Total undiscounted operating lease payments	2,048
Less: Imputed interest	(248)
Present value of operating lease liability	$ 1,800
Weighted average remaining lease term	8 years 1 month 6 days
Weighted average discount rate	3%

Schedule of Supplemental Cash F

Schedule of Supplemental Cash Flows Information Related to Leases (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2022 USD ($)
Leases
Operating cash flows from operating lease	$ 207

Leases (Details Narrative)

Leases (Details Narrative) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Leases
Operating lease expense	$ 246	$ 233

Schedule of Inventory (Details)

Schedule of Inventory (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Inventory Disclosure [Abstract]
Raw materials	$ 295	$ 178
Work-in-progress	51	88
Finished goods	156	25
Inventory, gross	502	291
Less: Inventory reserve for excess and slow moving inventory
Total	$ 502	$ 291

Schedule of Property and Equipm

Schedule of Property and Equipment (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 1,315	$ 1,218
Less: accumulated depreciation and amortization	(594)	(495)
Property and equipment, net	721	723
Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 973	940
Machinery and Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Useful Life (Years)	3 years
Machinery and Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Useful Life (Years)	10 years
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 59	50
Furniture and Fixtures [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Useful Life (Years)	3 years
Furniture and Fixtures [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Useful Life (Years)	10 years
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Useful Life (Years)	6 years
Property and equipment, gross	$ 228	228
Construction in Progress [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 55

Property and Equipment, Net (De

Property and Equipment, Net (Details Narrative) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 99	$ 99

Schedule of Breakdown of Identi

Schedule of Breakdown of Identifiable Intangible Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Finite-Lived Intangible Assets [Line Items]
Total	$ 20	$ 33
Technology-Based Intangible Assets [Member]
Finite-Lived Intangible Assets [Line Items]
Identifiable intangible assets, gross	31	31
Accumulated amortization	(26)	(16)
Total	5	15
Customer-Related Intangible Assets [Member]
Finite-Lived Intangible Assets [Line Items]
Identifiable intangible assets, gross	17	17
Trade Names [Member]
Finite-Lived Intangible Assets [Line Items]
Identifiable intangible assets, gross	7	7
Marketing-Related Intangible Assets [Member]
Finite-Lived Intangible Assets [Line Items]
Accumulated amortization	(9)	(6)
Total	$ 15	$ 18

Schedule of Estimated Annual Am

Schedule of Estimated Annual Amortization Expense (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
2023	$ 8
2024	2
2025	2
2026	2
2027	2
Thereafter	4
Total	$ 20	$ 33

Intangible Assets (Details Narr

Intangible Assets (Details Narrative) - Sport Defense LLC [Member] - Technology Related and Customer Related Intangibles [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	May 29, 2020
Finite-Lived Intangible Assets [Line Items]
Intangibles			$ 55
Expected life	5 years 1 month 6 days	5 years 1 month 6 days
Amortization expense	$ 13	$ 13

Schedule of Accrued Expenses an

Schedule of Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Payables and Accruals [Abstract]
Salaries, benefits, and incentive compensation	$ 56	$ 54
Franchise tax accrual	52
Other	22	8
Total accrued expenses and other current liabilities	$ 130	$ 62

Schedule of Reserved Common Sto

Schedule of Reserved Common Stock For Issuance in Relation (Details) - shares	1 Months Ended	12 Months Ended
	Aug. 31, 2022	Dec. 31, 2022
Equity [Abstract]
Share-based compensation plan		524,937
Warrants to purchase common Stock		3,637,190
Restricted stock units	84,750	90,432

Common Stock (Details Narrative

Common Stock (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended	12 Months Ended
	Dec. 27, 2021	Mar. 31, 2021	Dec. 31, 2021
Subsidiary, Sale of Stock [Line Items]
Number of units sold	2,585,000
Purchase price, per unit	$ 5.50
Exercise price	$ 5.50
Aggregate purchase price			$ 13,471
IPO [Member]
Subsidiary, Sale of Stock [Line Items]
Number of units sold	2,585,000
Purchase price, per unit	$ 5.50
Exercise price	$ 5.50
Additional number of days	45 days
Additional shares of common stock issued	387,750
Number of additional warrants issued	387,750
Underwriter [Member]
Subsidiary, Sale of Stock [Line Items]
Value of common stock offered on initial closing date	387,750
Private Placement [Member]
Subsidiary, Sale of Stock [Line Items]
Purchase price, per unit		$ 2.80
Issuances of common stock, net of issuance costs (in shares)		101,800
Aggregate purchase price		$ 285

Schedule of Information about I

Schedule of Information about Incentive Plan (Details) - shares			12 Months Ended
		Aug. 28, 2019	Dec. 31, 2022		May 26, 2020
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Awards Reserved For Issuance			571,429
Awards Issued			609,687
Awards Exercised			7,183
Awards Available for Grant
2019 Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Awards Reserved For Issuance			571,429	[1]	57,143
Awards Issued			564,246	[1]	485,715
Awards Exercised	[1]		7,183
Awards Available for Grant		57,143		[1]
Awards Issued In Excess of 2019 Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Awards Reserved For Issuance
Awards Issued			45,441
Awards Exercised
Awards Available for Grant
[1]includes incentive stock options and restricted stock units discussed below.

Schedule of Incentive Stock Opt

Schedule of Incentive Stock Option Activity (Details) - Equity Option [Member] - 2019 Plan [Member] - $ / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of options, outstanding, beginning balance	434,939	387,318
Weighted average exercise price, outstanding beginning balance	$ 1.678955	$ 1,124,418
Weighted average remaining contractual term	8 years 6 months 21 days	9 years 3 months 25 days
Number of options, granted	195,000	90,478
Weighted average exercise price, granted	$ 3.3461538	$ 3.960526
Weighted average remaining contractual term	10 years	10 years
Number of options, exercised		(7,183)
Weighted average exercise price, exercised		$ 1.75
Number of options, forfeited
Weighted average exercise price, forfeited
Number of options, cancelled	(100,001)	(28,571)
Weighted average exercise price, cancelled	$ 1.40000	$ 1.40
Number of options, expired	(5,001)	(7,103)
Weighted average exercise price, expired	$ 1.40000	$ 1.75
Number of options, outstanding, ending balance	524,937	434,939
Weighted average exercise price, outstanding ending balance	$ 2.351416	$ 1.678955
Weighted average remaining contractual term	8 years 4 months 17 days
Number of options, exercisable	379,937
Weighted average exercise price, exercisable	$ 1.777020
Weighted average remaining contractual term, exercisable	7 years 10 months 9 days

Schedule of Assumptions used in

Schedule of Assumptions used in Share-based Compensation (Details)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Volatility	277.84%
Risk-free interest rate	4.06%
Dividend yield	0%	0%
Expected term	5 years
Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Volatility		171.12%
Risk-free interest rate		0.46%
Expected term		5 years
Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Volatility		183.48%
Risk-free interest rate		0.86%
Expected term		5 years 9 months

Schedule of Restricted Stock Un

Schedule of Restricted Stock Units Grant (Details) - $ / shares	1 Months Ended	12 Months Ended
	Aug. 31, 2022	Dec. 31, 2022	Dec. 31, 2021
Share-Based Payment Arrangement [Abstract]
Number of units outstanding beginning			39,524
Weighted average grant date fair value outstanding ending			$ 2.10
Number of units, granted		96,114
Weighted average grant date fair value, granted		$ 1.61
Number of units, exercised and converted to common shares		(5,682)	(39,524)
Weighted average grant date fair value, exercised and converted to common shares	$ 1.82	$ 4.40	$ 2.10
Number of units, forfeited
Weighted average grant date fair value, forfeited
Number of units outstanding beginning		90,432
Weighted average grant date fair value outstanding ending		$ 1.43
Number of units exercisable		5,682
Weighted average grant date fair value exercisable		$ 4.40

Summary of Common Stock Warrant

Summary of Common Stock Warrants (Details) - $ / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Share-Based Payment Arrangement [Abstract]
Number of warrants, outstanding beginning balance	3,637,190	210,500
Weighted average exercise price, outstanding beginning balance	$ 5.16281	$ 0.85938
Weighted average remaining contractual term	4 years 7 months 17 days	2 years 6 months 14 days
Number of warrants, granted		3,426,690,000
Weighted average exercise price, granted		$ 5.42717
Weighted average remaining contractual term, Granted		4.98
Weighted average exercise price, exercised
Number of warrants, forfeited
Weighted average exercise price, forfeited
Number of warrants, cancelled
Weighted average exercise price, cancelled
Number of warrants, expired
Weighted average exercise price, expired
Number of warrants, outstanding ending balance	3,637,190	3,637,190
Weighted average exercise price, outstanding ending balance	$ 5.16281	$ 5.16281
Weighted average remaining contractual term	3 years 7 months 24 days
Number of warrants, exercisable	3,637,190
Weighted average exercise price, exercisable	$ 5.16281
Weighted average remaining contractual term, exercisable	3 years 7 months 24 days

Share-based Compensation (Detai

Share-based Compensation (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands

1 Months Ended

12 Months Ended

Oct. 01, 2022

Aug. 01, 2022

Jan. 01, 2022

Sep. 09, 2021

Mar. 08, 2021

Jan. 15, 2021

Aug. 28, 2019

Aug. 31, 2022

Jan. 31, 2022

Dec. 31, 2022

Dec. 31, 2021

Nov. 30, 2022

May 03, 2021

May 26, 2020

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Shares awarded

Common stock reserved for issuance

571,429

Number of options, granted

609,687

Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised

5,682

39,524

Restricted stock award shares, granted

96,114

Stock Issued During Period, Shares, Restricted Stock Award, Gross

84,750

90,432

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Exercises in Period, Weighted Average Grant Date Fair Value

$ 1.82

$ 4.40

$ 2.10

Share-based Payment Arrangement, Expense

$ 89

$ 285

Unrecognized Share-based Payment Arrangement, Expense

116

Intrinsic value of vested outstanding warrants

$ 114

$ 372

Restricted Stock [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Share Price

$ 4.40

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value

$ 50

Officers and Employees [Member | Restricted Stock [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Restricted stock award shares, granted

84,750

Stock Issued During Period, Shares, Restricted Stock Award, Gross

84,750

Share Price

$ 1.82

Chief Executive Officer [Member] | Restricted Stock [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Restricted stock award shares, granted

11,364

Stock Issued During Period, Shares, Restricted Stock Award, Gross

11,364

Share Price

$ 4.40

Chief Executive Officer and Chief Financial Officer [Member] | Restricted Stock [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Restricted stock award shares, granted

39,524

Stock Issued During Period, Shares, Restricted Stock Award, Gross

39,524

Share Price

$ 2.10

2019 Plan [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Shares awarded

57,143

[1]

Common stock reserved for issuance

571,429

[1]

57,143

Number of options, granted

564,246

[1]

485,715

Common stock reserved for issuance

300,000

485,715

Number of shares available for grant

571,429

[custom:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNumberExercised]

871,429

Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised

609,687

2019 Plan [Member] | Equity Option [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Number of options, granted

$ 3.3461538

$ 3.960526

Intrinsic value

$ 124

$ 408

Unrecognized share-based compensation expense

$ 0

2019 Plan [Member] | Equity Option [Member] | Maximum [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Period of recognition of stock based compensation expense

36 months

2019 Plan [Member] | Equity Option [Member] | Minimum [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Period of recognition of stock based compensation expense

18 months

2019 Plan [Member] | Executive Officer [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Number of options, granted

14,286

2019 Plan [Member] | Dr.Neil Chesen [Member] | Option One [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Number of options, granted

65,000

Number of options, granted

$ 2

Number of options, vested

15,000

Number of options, expected to vest

50,000

2019 Plan [Member] | Dr.Neil Chesen [Member] | Option Two [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Number of options, granted

25,000

Number of options, granted

$ 2

2019 Plan [Member] | Dr.Neil Chesen [Member] | Option Three [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Number of options, granted

37,500

Number of options, granted

$ 5.50

2019 Plan [Member] | Dr.Neil Chesen [Member] | Option Three [Member] | Maximum [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Expiration period

36 months

2019 Plan [Member] | Dr.Leonard Nelson [Member] | Option One [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Number of options, granted

30,000

Number of options, granted

$ 2

Number of options, vested

5,000

Number of options, expected to vest

25,000

Expiration period

10 years

2019 Plan [Member] | Dr.Leonard Nelson [Member] | Option One [Member] | Maximum [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Expiration period

18 months

2019 Plan [Member] | Dr.Leonard Nelson [Member] | Option Two [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Number of options, granted

37,500

Number of options, granted

$ 5.50

Expiration period

10 years

2019 Plan [Member] | Dr.Leonard Nelson [Member] | Option Two [Member] | Maximum [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Expiration period

36 months

2019 Plan [Member] | Contractor [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Number of options, granted

14,286

Number of options, granted

$ 2.80

Number of options, vested

2,857

Number of options, expected to vest

11,429

2019 Plan [Member] | Dr.Jerome Zeldis [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Number of options, granted

19,048

Number of options, granted

$ 2.80

2019 Plan [Member] | Steven Glassman [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Number of options, granted

14,286

Number of options, granted

$ 2.80

2019 Plan [Member] | Adam Levy [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Number of options, granted

14,286

Number of options, granted

$ 5.25

2019 Plan [Member] | Yaakov Spinrad [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Number of options, granted

14,286

2019 Plan [Member] | MirandaJ Toledano [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Number of options, granted

14,286

[1]includes incentive stock options and restricted stock units discussed below.

Schedule Of Debt Instruments (D

Schedule Of Debt Instruments (Details) $ in Thousands	Dec. 31, 2022 USD ($)
Debt Disclosure [Abstract]
2023	$ 5
2024	5
2025	5
2026	6
2027	6
Thereafter	256
Total	$ 283

Notes Payable (Details Narrativ

Notes Payable (Details Narrative) - USD ($) $ in Thousands		12 Months Ended
	May 28, 2020	Dec. 31, 2022	Dec. 31, 2021	Nov. 16, 2021	Jun. 02, 2021	Mar. 04, 2021	Apr. 22, 2020
Short-Term Debt [Line Items]
Loan amount		$ 283
Accrued interest		$ 283	$ 276
Paycheck Protection Program Loan [Member]
Short-Term Debt [Line Items]
Loan amount				$ 127,400	$ 147,300	$ 127,400	$ 147,300
Economic Injury Disaster Loan [Member]
Short-Term Debt [Line Items]
Borrowing capacity	$ 260,500
Interest rate	3.75%
DebtInstrument periodic payment	$ 1,270
Term of the loan	30 years
Loan advance	$ 8

Convertible Notes Payable (Deta

Convertible Notes Payable (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands		12 Months Ended
	Sep. 02, 2021	Dec. 31, 2022	Dec. 31, 2021	Jan. 25, 2022	Sep. 06, 2021	Jan. 19, 2021	Dec. 24, 2020
Short-Term Debt [Line Items]
Gains loss on extinguishment of debt		$ (150)	$ (25)
Convertible Promissory Note [Member]
Short-Term Debt [Line Items]
Principal amount of debt						$ 15	$ 100
Interest rate, percentage							6%
Conversion price						$ 1.05	$ 2.80
Secured Convertible Promissory Note [Member]
Short-Term Debt [Line Items]
Interest expense	$ 194
Outstanding principal and accrued unpaid interest				$ 300
Pre payment penalty				17
Unamortized debt discount				$ 133
Gains loss on extinguishment of debt		$ 150
Secured Convertible Promissory Note [Member] | Private Placement [Member]
Short-Term Debt [Line Items]
Principal amount of debt	$ 1,814				$ 1,478

Schedule of Warrant Liability (

Schedule of Warrant Liability (Details) $ / shares in Units, $ in Thousands			12 Months Ended
		Sep. 06, 2022 USD ($)	Dec. 31, 2022 USD ($) Integer shares	Dec. 31, 2021 USD ($) Integer $ / shares shares
Fair value | $			$ 318
Modification of warrants | $		$ 57	57	$ 52
Change in fair value of warrant liability | $			(133)	(8)
Fair value | $			$ 242	$ 318
Warrant sIssuance On September 2 2021 [Member] | Measurement Input, Exercise Price [Member]
Warrants Fair value	[1]		0.0525
Warrant sIssuance On September 2 2021 [Member] | Measurement Input, Share Price [Member]
Warrants Fair value	[1],[2]		3.50
Warrant sIssuance On September 2 2021 [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrants Fair value	[1],[3]		0.78
Warrant sIssuance On September 2 2021 [Member] | Measurement Input, Option Volatility [Member]
Warrants Fair value	[1],[4]		182.74
Warrant sIssuance On September 2 2021 [Member] | Measurement Input, Expected Term [Member]
Warrants Fair value	[1]		5 years
Warrant sIssuance On September 2 2021 [Member] | Measurement Input, Quoted Price [Member]
Warrants Fair value	[1]		0.3325
Warrants Issuance One [Member]
Warrants Fair value	[1],[5]
Warrants Issuance On March 11 2021 [Member] | Minimum [Member]
Warrants Fair value	[6]		4.375
Warrants Issuance On March 11 2021 [Member] | Measurement Input, Share Price [Member]
Warrants Fair value	[2],[6]		3.50
Warrants Issuance On March 11 2021 [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrants Fair value	[3],[6]			0.17
Warrants Issuance On March 11 2021 [Member] | Measurement Input, Option Volatility [Member]
Warrants Fair value	[4],[6]		172.54
Warrants Issuance On March 11 2021 [Member] | Measurement Input, Expected Term [Member]
Warrants Fair value	[6]		5 years
Warrants Issuance On March 11 2021 [Member] | Measurement Input, Quoted Price [Member] | Minimum [Member]
Warrants Fair value	[6]		0.3325
Warrants Issuance On March 11 2021 [Member] | Measurement Input, Quoted Price [Member] | Maximum [Member]
Warrants Fair value	[6]		0.0329
Warrants Issuance On March 11 2021, Expiring On March 11 2026 | Maximum [Member]
Warrants Fair value	[6]		5.25
Warrants Issuance Two [Member]
Warrants Fair value	[5],[6]
Warrants Issuance On February 03, 2021, Expiring on February 3, 2024 | Measurement Input, Exercise Price [Member]
Warrants Fair value	[7]			2.80
Warrants Issuance On February 03, 2021, Expiring on February 3, 2024 | Measurement Input, Share Price [Member]
Warrants Fair value	[2],[7]		2.80
Warrants Issuance On February 03, 2021, Expiring on February 3, 2024 | Measurement Input, Risk Free Interest Rate [Member]
Warrants Fair value	[3],[7]		0.18
Warrants Issuance On February 03, 2021, Expiring on February 3, 2024 | Measurement Input, Option Volatility [Member]
Warrants Fair value	[4],[7]		171.71
Warrants Issuance On February 03, 2021, Expiring on February 3, 2024 | Measurement Input, Expected Term [Member]
Warrants Fair value	[7]		3 years
Warrants Issuance On February 03, 2021, Expiring on February 3, 2024 | Measurement Input, Quoted Price [Member]
Warrants Fair value	[7]		2.417461
Warrants Issuance Three [Member]
Warrants Fair value	[5],[7]
Warrants Issuances On December 24, 2020, Expiring On December 24, 2023 | Measurement Input, Share Price [Member]
Warrants Fair value	[2],[8]		2.80
Warrants Issuances On December 24, 2020, Expiring On December 24, 2023 | Measurement Input, Risk Free Interest Rate [Member]
Warrants Fair value	[3],[8]		0.17
Warrants Issuances On December 24, 2020, Expiring On December 24, 2023 | Measurement Input, Option Volatility [Member]
Warrants Fair value	[4],[8]		172.54
Warrants Issuances On December 24, 2020, Expiring On December 24, 2023 | Measurement Input, Expected Term [Member]
Warrants Fair value	[8]		3 years
Warrants Issuances On December 24, 2020, Expiring On December 24, 2023 | Measurement Input, Quoted Price [Member]
Warrants Fair value	[8]		2.422658
Warrants Issuance Four [Member]
Warrants Fair value	[5],[8]
Warrants Issuance on March 18, 2020, Expiring on March 18, 2023 | Measurement Input, Exercise Price [Member]
Warrants Fair value	[9]		1.40
Warrants Issuance on March 18, 2020, Expiring on March 18, 2023 | Measurement Input, Share Price [Member]
Warrants Fair value	[2],[9]		1.40
Warrants Issuance on March 18, 2020, Expiring on March 18, 2023 | Measurement Input, Risk Free Interest Rate [Member]
Warrants Fair value	[3],[9]		0.66
Warrants Issuance on March 18, 2020, Expiring on March 18, 2023 | Measurement Input, Option Volatility [Member]
Warrants Fair value	[4],[9]		137.41
Warrants Issuance on March 18, 2020, Expiring on March 18, 2023 | Measurement Input, Expected Term [Member]
Warrants Fair value	[9]		3 years
Warrants Issuance on March 18, 2020, Expiring on March 18, 2023 | Measurement Input, Quoted Price [Member]
Warrants Fair value	[9]		1.075547
Warrants Issuance Five [Member]
Warrants Fair value	[5],[9]
Warrants Issuance on September 10, 2019, Expiring on September 10, 2022 | Measurement Input, Share Price [Member]
Warrants Fair value	[2],[10]		0.49
Warrants Issuance on September 10, 2019, Expiring on September 10, 2022 | Measurement Input, Risk Free Interest Rate [Member]
Warrants Fair value	[3],[10]		1.61
Warrants Issuance on September 10, 2019, Expiring on September 10, 2022 | Measurement Input, Option Volatility [Member]
Warrants Fair value	[4],[10]			139.84
Warrants Issuance on September 10, 2019, Expiring on September 10, 2022 | Measurement Input, Expected Term [Member]
Warrants Fair value	[10]		3 years
Warrants Issuance on September 10, 2019, Expiring on September 10, 2022 | Measurement Input, Quoted Price [Member]
Warrants Fair value	[10]		0.38185
Warrants Issuance Six [Member]
Warrants Fair value	[5],[10]
Warrants Issuance on November 6, 2019, Expiring on November 6, 2022 | Measurement Input, Share Price [Member]
Warrants Fair value	[11]		0.49	0.49	[2]
Warrants Issuance on November 6, 2019, Expiring on November 6, 2022 | Measurement Input, Risk Free Interest Rate [Member]
Warrants Fair value	[3],[11]		1.60
Warrants Issuance on November 6, 2019, Expiring on November 6, 2022 | Measurement Input, Option Volatility [Member]
Warrants Fair value	[4],[11]		138.48
Warrants Issuance on November 6, 2019, Expiring on November 6, 2022 | Measurement Input, Expected Term [Member]
Warrants Fair value	[11]		3 years
Warrants Issuance on November 6, 2019, Expiring on November 6, 2022 | Measurement Input, Quoted Price [Member]
Warrants Fair value	[11]		0.38255
Warrants Issuance Seven [Member]
Warrants Fair value	[5],[11]
Warrants Issuance On December 31 2022 One [Member] | Measurement Input, Exercise Price [Member]
Warrants Fair value	[1]		0.0525
Warrants Issuance On December 31 2022 One [Member] | Measurement Input, Share Price [Member]
Warrants Fair value	[1],[2]		1.25
Warrants Issuance On December 31 2022 One [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrants Fair value	[1],[3]			4.22
Warrants Issuance On December 31 2022 One [Member] | Measurement Input, Option Volatility [Member]
Warrants Fair value	[1],[4]		287.87
Warrants Issuance On December 31 2022 One [Member] | Measurement Input, Expected Term [Member]
Warrants Fair value	[1]		3 years 8 months 4 days
Warrants Issuance On December 31 2022 One [Member] | Measurement Input, Quoted Price [Member]
Warrants Fair value	[1]		0.0968371
Warrants Issuance On December 31 2022 Two [Member] | Minimum [Member]
Warrants Fair value	[6]		4.375
Warrants Issuance On December 31 2022 Two [Member] | Maximum [Member]
Warrants Fair value	[6]		5.25
Warrants Issuance On December 31 2022 Two [Member] | Measurement Input, Share Price [Member]
Warrants Fair value	[2],[6]		1.25
Warrants Issuance On December 31 2022 Two [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrants Fair value	[3],[6]		4.22
Warrants Issuance On December 31 2022 Two [Member] | Measurement Input, Option Volatility [Member]
Warrants Fair value	[4],[6]		288.66
Warrants Issuance On December 31 2022 Two [Member] | Measurement Input, Expected Term [Member]
Warrants Fair value	[6]		3 years 2 months 12 days
Warrants Issuance On December 31 2022 Two [Member] | Measurement Input, Quoted Price [Member] | Minimum [Member]
Warrants Fair value	[6]		0.096101
Warrants Issuance On December 31 2022 Two [Member] | Measurement Input, Quoted Price [Member] | Maximum [Member]
Warrants Fair value	[6]		0.0957467
Warrants Issuance On December 31 2022 Three [Member] | Measurement Input, Exercise Price [Member]
Warrants Fair value	[7]		2.80
Warrants Issuance On December 31 2022 Three [Member] | Measurement Input, Share Price [Member]
Warrants Fair value	[2],[7]		1.25
Warrants Issuance On December 31 2022 Three [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrants Fair value	[3],[7]		4.73
Warrants Issuance On December 31 2022 Three [Member] | Measurement Input, Option Volatility [Member]
Warrants Fair value	[4],[7]		352.74
Warrants Issuance On December 31 2022 Three [Member] | Measurement Input, Expected Term [Member]
Warrants Fair value	[7]		1 year 1 month 6 days
Warrants Issuance On December 31 2022 Three [Member] | Measurement Input, Quoted Price [Member]
Warrants Fair value	[7]		0.0690620
Warrants Issuances On December 31 2022 Four [Member] | Measurement Input, Exercise Price [Member]
Warrants Fair value	[8]		2.80
Warrants Issuance On December 31 2022 Four [Member] | Measurement Input, Share Price [Member]
Warrants Fair value	[2],[8]		1.25
Warrants Issuance On December 31 2022 Four [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrants Fair value	[3],[8]		4.73
Warrants Issuance On December 31 2022 Four [Member] | Measurement Input, Option Volatility [Member]
Warrants Fair value	[4],[8]		331
Warrants Issuance On December 31 2022 Four [Member] | Measurement Input, Expected Term [Member]
Warrants Fair value	[8]		11 months 23 days
Warrants Issuance On December 31 2022 Four [Member] | Measurement Input, Quoted Price [Member]
Warrants Fair value	[8]		0.0681813
Warrants Issuance On December 31 2022 Five [Member] | Measurement Input, Exercise Price [Member]
Warrants Fair value	[9]		1.40
Warrants Issuance On December 31 2022 Five [Member] | Measurement Input, Share Price [Member]
Warrants Fair value	[2],[9]		1.25
Warrants Issuance On December 31 2022 Five [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrants Fair value	[3],[9]		4.42
Warrants Issuance On December 31 2022 Five [Member] | Measurement Input, Option Volatility [Member]
Warrants Fair value	[4],[9]		147.61
Warrants Issuance On December 31 2022 Five [Member] | Measurement Input, Expected Term [Member]
Warrants Fair value	[9]		2 months 19 days
Warrants Issuance On December 31 2022 Five [Member] | Measurement Input, Quoted Price [Member]
Warrants Fair value	[9]		0.0296661
Warrants Issuance On December 31 2022 Six [Member] | Measurement Input, Exercise Price [Member]
Warrants Fair value	[10]		0.49
Warrants Issuance On December 31 2022 Six [Member] | Measurement Input, Share Price [Member]
Warrants Fair value	[2],[10]		1.25
Warrants Issuance On December 31 2022 Six [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrants Fair value	[3],[10]		4.42
Warrants Issuance On December 31 2022 Six [Member] | Measurement Input, Option Volatility [Member]
Warrants Fair value	[4],[10]		137.02
Warrants Issuance On December 31 2022 Six [Member] | Measurement Input, Expected Term [Member]
Warrants Fair value	[10]		4 months 6 days
Warrants Issuance On December 31 2022 Six [Member] | Measurement Input, Quoted Price [Member]
Warrants Fair value	[10]		0.0091855
Warrants Issuance On December 31 2022 Seven [Member] | Measurement Input, Exercise Price [Member]
Warrants Fair value	[11]		0.49
Warrants Issuance On December 31 2022 Seven [Member] | Measurement Input, Share Price [Member]
Warrants Fair value	[2],[11]			1.25
Warrants Issuance On December 31 2022 Seven [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrants Fair value	[3],[11]		4.42
Warrants Issuance On December 31 2022 Seven [Member] | Measurement Input, Option Volatility [Member]
Warrants Fair value	[4],[11]		149.27
Warrants Issuance On December 31 2022 Seven [Member] | Measurement Input, Expected Term [Member]
Warrants Fair value	[11]		2 months 4 days
Warrants Issuance On December 31 2022 Seven [Member] | Measurement Input, Quoted Price [Member]
Warrants Fair value	[11]		0.0085006
Warrants Issuance On December 31, 2021, Expiring on September 2, 2026 | Measurement Input, Exercise Price [Member]
Warrants Fair value	[1]		0.0525
Warrants Issuance On December 31, 2021, Expiring on September 2, 2026 | Measurement Input, Share Price [Member]
Warrants Fair value	[1],[2]		3.50
Warrants Issuance On December 31, 2021, Expiring on September 2, 2026 | Measurement Input, Risk Free Interest Rate [Member]
Warrants Fair value	[1],[3]			0.98
Warrants Issuance On December 31, 2021, Expiring on September 2, 2026 | Measurement Input, Option Volatility [Member]
Warrants Fair value	[1],[4]		205.16
Warrants Issuance On December 31, 2021, Expiring on September 2, 2026 | Measurement Input, Expected Term [Member]
Warrants Fair value	[1]		4 years 8 months 1 day
Warrants Issuance On December 31, 2021, Expiring on September 2, 2026 | Measurement Input, Quoted Price [Member]
Warrants Fair value	[1]		0.0968371
Warrants Issuance On December 31, 2021, Expiring on March 11, 2026 | Minimum [Member]
Warrants Fair value	[6]		4.375
Warrants Issuance On December 31, 2021, Expiring on March 11, 2026 | Maximum [Member]
Warrants Fair value	[6]		5.25
Warrants Issuance On December 31, 2021, Expiring on March 11, 2026 | Measurement Input, Share Price [Member]
Warrants Fair value	[2],[6]		3.50
Warrants Issuance On December 31, 2021, Expiring on March 11, 2026 | Measurement Input, Risk Free Interest Rate [Member]
Warrants Fair value	[3],[6]		0.98
Warrants Issuance On December 31, 2021, Expiring on March 11, 2026 | Measurement Input, Option Volatility [Member]
Warrants Fair value	[4],[6]		205.16
Warrants Issuance On December 31, 2021, Expiring on March 11, 2026 | Measurement Input, Expected Term [Member]
Warrants Fair value	[6]		4 years 2 months 8 days
Warrants Issuance On December 31, 2021, Expiring on March 11, 2026 | Measurement Input, Quoted Price [Member] | Minimum [Member]
Warrants Fair value	[6]		0.096101
Warrants Issuance On December 31, 2021, Expiring on March 11, 2026 | Measurement Input, Quoted Price [Member] | Maximum [Member]
Warrants Fair value	[6]		0.0957467
Warrants Issuance On December 31 2021 Three [Member] | Measurement Input, Exercise Price [Member]
Warrants Fair value	[7]		2.80
Warrants Issuance On December 31 2021 Three [Member] | Measurement Input, Share Price [Member]
Warrants Fair value	[2],[7]		2.80
Warrants Issuance On December 31 2021 Three [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrants Fair value	[3],[7]		0.28
Warrants Issuance On December 31 2021 Three [Member] | Measurement Input, Option Volatility [Member]
Warrants Fair value	[4],[7]		205.16
Warrants Issuance On December 31 2021 Three [Member] | Measurement Input, Expected Term [Member]
Warrants Fair value	[7]		2 years 1 month 2 days
Warrants Issuance On December 31 2021 Three [Member] | Measurement Input, Quoted Price [Member]
Warrants Fair value	[7]		0.0690620
Warrants Issuance On December 31 2021 Four [Member] | Measurement Input, Exercise Price [Member]
Warrants Fair value	[8]		2.80
Warrants Issuance On December 31 2021 Four [Member] | Measurement Input, Share Price [Member]
Warrants Fair value	[2],[8]		2.80
Warrants Issuance On December 31 2021 Four [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrants Fair value	[3],[8]		0.28
Warrants Issuance On December 31 2021 Four [Member] | Measurement Input, Option Volatility [Member]
Warrants Fair value	[4],[8]		205.16
Warrants Issuance On December 31 2021 Four [Member] | Measurement Input, Expected Term [Member]
Warrants Fair value	[8]		1 year 11 months 23 days
Warrants Issuance On December 31 2021 Four [Member] | Measurement Input, Quoted Price [Member]
Warrants Fair value	[8]		0.0681813
Warrants Issuance On December 31 2021 Five [Member] | Measurement Input, Exercise Price [Member]
Warrants Fair value	[9]		1.40
Warrants Issuance On December 31 2021 Five [Member] | Measurement Input, Share Price [Member]
Warrants Fair value	[2],[9]		1.40
Warrants Issuance On December 31 2021 Five [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrants Fair value	[3],[9]		0.28
Warrants Issuance On December 31 2021 Five [Member] | Measurement Input, Option Volatility [Member]
Warrants Fair value	[4],[9]		205.16
Warrants Issuance On December 31 2021 Five [Member] | Measurement Input, Expected Term [Member]
Warrants Fair value	[9]		1 year 2 months 15 days
Warrants Issuance On December 31 2021 Five [Member] | Measurement Input, Quoted Price [Member]
Warrants Fair value	[9]		0.0296661
Warrants Issuance On December 31 2021 Six [Member] | Measurement Input, Exercise Price [Member]
Warrants Fair value	[10]		0.49
Warrants Issuance On December 31 2021 Six [Member] | Measurement Input, Share Price [Member]
Warrants Fair value	[2],[10]		0.49
Warrants Issuance On December 31 2021 Six [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrants Fair value	[3],[10]		0.09
Warrants Issuance On December 31 2021 Six [Member] | Measurement Input, Option Volatility [Member]
Warrants Fair value	[4],[10]		205.16
Warrants Issuance On December 31 2021 Six [Member] | Measurement Input, Expected Term [Member]
Warrants Fair value	[10]		8 months 8 days
Warrants Issuance On December 31 2021 Six [Member] | Measurement Input, Quoted Price [Member]
Warrants Fair value	[10]		0.0091855
Warrants Issuance On December 31 2021 Seven [Member] | Measurement Input, Exercise Price [Member]
Warrants Fair value	[11]		0.49
Warrants Issuance On December 31 2021 Seven [Member] | Measurement Input, Share Price [Member]
Warrants Fair value	[2],[11]		0.49
Warrants Issuance On December 31 2021 Seven [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrants Fair value	[3],[11]		0.19
Warrants Issuance On December 31 2021 Seven [Member] | Measurement Input, Option Volatility [Member]
Warrants Fair value	[4],[11]		205.16
Warrants Issuance On December 31 2021 Seven [Member] | Measurement Input, Expected Term [Member]
Warrants Fair value	[11]		10 months 6 days
Warrants Issuance On December 31 2021 Seven [Member] | Measurement Input, Quoted Price [Member]
Warrants Fair value	[11]		0.0085006
Warrant [Member]
Warrants outstanding | shares			265,305	201,572
Fair value | $			$ 318	$ 123
Fair value at initial measurement | $				$ 63,733
Fair value at initial measurement | $ / shares				$ 3.2097
Modification of warrants | $			57	$ 203
Change in fair value of warrant liability | $			$ (133)	$ (8)
Warrant modification | shares
Change in fair value of warrant liability | shares
Warrants outstanding | shares			265,305	265,305
Fair value | $			$ 242	$ 318
[1]Based on the terms provided in the warrant agreement related to the issuance of common stock of on September 2 nd th rd th th th th

Warrant Liability (Details Narr

Warrant Liability (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands		12 Months Ended
	Sep. 06, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 27, 2021	Sep. 02, 2021	Mar. 11, 2021	Feb. 03, 2021	Dec. 24, 2020	Mar. 18, 2020	Nov. 06, 2019	Sep. 10, 2019
Subsidiary, Sale of Stock [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 5.50
Warrant modification expense	$ 57	$ 57	$ 52
Private Placement [Member]
Subsidiary, Sale of Stock [Line Items]
Class of Warrant or Right, Outstanding					22,019	34,285	7,429	7,286	44,286	114,286	35,714
Private Placement [Member] | Minimum [Member]
Subsidiary, Sale of Stock [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.49
Private Placement [Member] | Maximum [Member]
Subsidiary, Sale of Stock [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 5.25

Concentrations of Risk (Details

Concentrations of Risk (Details Narrative) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Concentration Risk [Line Items]
Cash, FDIC insured amount	$ 250
Cash, exceeding	$ 501
Customer One [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage	29%	15%
Customer One [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage	40%	45%
Customer Two [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage		14%
Customer Two [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage	22%	20%
Customer Three [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage		13%
Customer Three [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage	18%	12%

Related Party Transactions (Det

Related Party Transactions (Details Narrative) $ in Thousands	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Sep. 02, 2021 USD ($) Integer	Dec. 24, 2020 USD ($) Integer
Mr. Stein [Member]
Related Party Transaction [Line Items]
Number Of Debt Instruments | Integer			3	2
Debt Instrument, Face Amount			$ 150,000	$ 100,000
Mr.Stefansky Member Of Board Of Directors [Member]
Related Party Transaction [Line Items]
Debt Instrument, Face Amount			150,000
Dr.Jerome Zeldis [Member]
Related Party Transaction [Line Items]
Debt Instrument, Face Amount			$ 50,000
Due from Related Parties, Current	$ 40,000	$ 40,000

Schedule of income tax (benefit

Schedule of income tax (benefit) provision (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Federal:
Current
Deferred
State and local:
Current
Deferred
Income tax provision

Schedule of Effective Income Ta

Schedule of Effective Income Tax Rate Reconciliation (Details)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Income Tax Disclosure [Abstract]
U.S. federal statutory rate	21%	21%
State tax rate, net of federal benefit	5.30%	5.30%
Non-deductible expenses	(9.70%)	(10.50%)
Timing differences	(0.00%)	0.60%
Change in valuation allowance	(16.60%)	(16.40%)
Income tax provision	0%	0%

Schedule of Deferred Tax Assets

Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Net operating loss carryforwards	$ 4,112	$ 3,326
Other	6	4
Total deferred tax assets	4,118	3,330
Valuation allowance	(4,118)	(3,330)
Deferred tax assets, net of valuation allowance
Property and equipment, net
Total deferred tax liabilities
Net deferred tax liabilities

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Income Tax Expense (Benefit)	$ 0	$ 0
Unrecognized Tax Benefits	0	0
Deferred Tax Assets, Operating Loss Carryforwards, State and Local	15,600,000	12,600,000
PANAMA
Deferred Tax Assets, Operating Loss Carryforwards, State and Local	$ 15,600,000	$ 12,600,000

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)			12 Months Ended
	Mar. 23, 2023	Mar. 21, 2023	Dec. 31, 2022		Mar. 01, 2023	May 26, 2020
Subsequent Event [Line Items]
Number of shares available for grant			609,687
2019 Plan [Member]
Subsequent Event [Line Items]
Number of shares available for grant			564,246	[1]		485,715
[custom:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNumberExercised]			871,429
Subsequent Event [Member]
Subsequent Event [Line Items]
Payments to Acquire Interest in Joint Venture		$ 500,000
Subsequent Event [Member] | 2019 Plan [Member]
Subsequent Event [Line Items]
Convertible Preferred Stock, Shares Issued upon Conversion	300,000
Number of shares available for grant	571,429
[custom:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNumberExercised]	871,429
CGLaboratories [Member]
Subsequent Event [Line Items]
Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage					50%
[1]includes incentive stock options and restricted stock units discussed below.